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An abundance of genetic, b iochemical and histopathological evidence 
uggests that the [onnat ion of a-synuclein (a-syn) protein deposits is an important, 
and l ikely seminal ,  step in the development of several important neurodegenerative 
disease, the o-cal led synucleinopathies, including Parkinson's Disease (PD) 
dem ntia wi th Lewy bodies and multip le-system atrophy. Despite decades of 
intensive re earch, to date, the only accepted diagnosis for PD is based on cl inical 
criteria. a-Syn conversion from soluble monomer into o l igomers or fibri ls  represents 
a rucial tep in synuc leinopathies pathogenesis; however the exact mechanism 
und rl i ng the cel l u lar aggregation has not been ful ly e lucidated. A growing body of 
evidence sugge ts that a-syn soluble o l igomers, rather than mature fibri ls, are the 
neurotoxic p c ies. A lack of biomarkers for the early diagnosis of PD is a major 
obstac le to providing early disease-modi fying therapies. Toward this aim, we 
developed and thoroughly characterized novel confonnation-spec ific monoclonal 
antibod i es that speci fical ly recogn ize a-syn pathology. I mportantly, our antibodies 
were able to detect di fferent assembl ies of a-syn aggregates ranging from sol uble 
o l igomers to mature in o luble fibri ls .  Considering the crit ical pathogen ic ro le of a­
syn soluble aggregates our novel antibodies might provide important diagnostic and 
therapeutic opportunities. 
Next, we developed new immunoassays to quanti fy di fferent species of a-syn 
(total a-syn. a-syn ol igomers and p-S 1 29-a-syn) levels in cerebrospinal fluid (CSF) 
from P D  patients and age-matched healthy controls. Combining the measurements of 
di fferent a-syn species in  CSF, we found a clear di fferential CSF pattern between PD 
viii 
and controls. Our results v al idated the usefulness of combining multiple CSF 
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CHAPT E R  ON E :  I n troduction 
1 
1.1 Parkinson 's disea e 
eurodegenerative diseases are the leading cause for disabil ity in the world 
and one of the bigge t burdens on our societies. Parkinson's Disease (PO) is the 
second rna t common neurodegenerative disease after Alzheimer's Disease (AD), 
and P O  j a chronic pr gressive irreversible disorder. PO was ftrst described by 
Jame Park inson, an Engl ish physic ian, in his assay Shaking Palsy" over 1 00 
years ago. Although in less than three years PO wi l l  enter i ts next century many 
a pect of the di ease remain to be eluc idated. 
PO affects mainly a region within the midbrain known as the substantia nigra 
( ) which i the main center of  the dopaminergic  neurons. Dopamine (DA), a 
neurotransmitter that is mainly involved in  the control of the movement in our 
bodies is  synthesized within dopaminergic neurons. Degeneration of these 
neurons result in reduced levels of DA. The c l i nical symptoms of PO manifest 
when degeneration affects 75% of these neurons. The cardinal symptoms of P O  
are: 1 )  Resting tremor: haking that is  mainly seen in the hands and jaw, 2 )  
Rigidity: patient ftnds i t  d ifftcult  to move h i s  l imbs, 3 )  Bradykinesia: slowness i n  
movement and 4) Postural instabi l ity. 
In 1 9 1 2, while Frederick Lewy was examining the brains of people with PO, 
he noticed abnonnal microscopic structures which are now known by Lewy bodies 
( LBs) .  LBs and Lewy neurites (LNs) are the neuropathlogical hal lmark of PO and 
dementia with Lewy bodies ( OLB). LBs are eosinophi l ic  intracytplasmic 
inclusions that are mainly composed of the protein named alpha-synuc lein (a-syn) .  
2 
1.2 Epidemiology 
PD i s  the second most common neurodegenerative disease. The soci al and 
economic burden imposed by PD is sign ificantly increasing as populations age. In 
2007, Dorsey et a/." expected that the number of people  affected by PD wi l l  rise to 
9.3 mi l l ion in 2030 ( Dorsey et at. ,  2007). In 2009, M uangpaisan et af" concluded 
in hi systematic review that PO prevalence and incidence is sl ightly lower in  
A ian countries as compared to Western countries (Muangpaisan, Hori, & Brayne, 
2009). However no significant di fference was seen in the occurrence of PD 
between Asians from d ifferent ethnic groups (L .  C .  Tan et  at . ,  2004). I n  2009, 
Y amawaki el al., reported that the occurrence and risk of  developing PD has 
remained stable  over 25 years (Yamawaki, Kusumi ,  Kowa & Nakashima, 2009). 
e erthele the burden of  PO in Asia is significantly increasing as a result of  
i ncrea ed l i fe expectancy and population ageing. 
A recent study conducted in United States estimated that approximately  
630,000 people  in U S  were diagnosed with PD in 2010, and this number i s  most 
l ikely to double by 2040, whi l e  the national economic burden of PO exceeded 
S14.4 b i l l ion in 2010 (Kowal ,  Dal l ,  Chakrabarti ,  Storm, & Jain, 2013). 
The question st i l l  remains whether prevalence rates vary between males and 
females. Some studies reported a higher prevalence of PD in men than in women 
( Benito-Le6n et a l .  2004; Benito-Le6n et aI . ,  2003; Fal l et at. , 1996; Mayeux et 
aI . ,  1995), whereas other studies found no significant d ifferences in PD prevalence 
between men and women (de Lau et at. ,  2004; de Rij k  et a I . ,  1995; de Rijk  et at. ,  
1997; Morgante et  aI . ,  1992). The reason for higher risk of PD in men than women 
3 
i s  most ly explained by the di fference in estrogens l evels; however this explanation 
is t i l l  being debated (Cardona-Rossinyol, Mir, Caraballo-Miral les, L lad6 & 
Olmos, 2013; Morissette, Al Sweidi,  Call ier, & Di  P aolo, 2008; Saunders-Pullman, 
2003). 
1. 3 Neuropathology 
PD can be poradic or inheri ted, and in both cases it is accompanied by 
degeneration of neurons in the pars compacta of the SN which proj ects to putamen. 
This mainly rc ults in a disruption of the nigrostraital dopaminergic  system. It is  
mostly d ifficult to diagnose PD at early stages due to the compensatory mechanism 
of the surviving dopaminergic neurons. Once the loss exceeds 75%, this 
mechanism fai l s  to compensate and the c l inical symptoms of PD start to appear. 
Remarkably, the midbrain remains signi ficantly  unaffected, which is helpful in the 
differential d iagnosis of PD from other related parkinsonism disorders l ike 
progressive supraneural palsy and mUltiple system atrophy (MSA). 
1 .3.1 Lew)' bodies and Lewy neuri tes.  
LBs and L s are the most common neuropathology of PD, and mainly but not 
exclusively exist in the S . LBs and LNs are also present in other brain regions 
l ike dorsal motor nucleus of the vagus, the nucleus basal is of Meynert, and the 
locus coeruleus. LBs are mainly intracel lu lar spherical assembl ies with dense 
eosinoph i l ic core surrounding a pale halo, whi le L s are long filaments that shares 
the same composition. Brain sections rich with LBs and LNs from patients with 
confirmed DLB were strongly stained with antibodies directed against a-syn but 
4 
not beta-")1 uclem (p- yn) or gamma- )11uclein (y- )11) (Splliantini, Crowther, 
Jake, IIasegawa. & Goedert. 1 99 ; Spillantini et a1.. 1 997) .  The e ection al 0 
tained po itive for ubiquitin, but with Ie s in inten ity and number, suggesting that 












Fig. 1 . 1  Lewy bodies and Lewy neurites in post-mortem brain 
Sub tanlia nigra from patients with PD (A-F) immunostained for 
a- )11 (in brown). 
1 .3.2 Mitochondria dysfunction 
-
Mitochondria are unique structures with a double lipid bilayer membrane and 
are found in all eukaryotic cells. These organelles generate energy in the form of 
adenosine tripho phate (ATP) through the electron transport chain. Mitochondria 
plays essential roles in maintaining calcium hemo tasis and mediating 
programmed cell death "apoptosis". The electron tran port chain is composed of 
five complexes, deficiency or inhibition of any of these complexes leads to 
disruption of this chain resulting in mitochondrial dysfunction and free radicals 
5 
amounts of A TP, they are rich in with mitochondria. The first piece of evidence 
that linked mitochondrial dysfunction with PD is the neurotoxin MPTP ((l-methyl-
4-phenyl- l 2 3, 6-tetrahydropyridine). MPTP causes parkinsonian symptoms 
similar to those seen in PD patients by inhibiting Complex 1 in electron transport 
chain thu decreasing ATP levels and increasing ROS production. The link 
between dopamenrgic neurons susceptibility and mitochondrial dysfunction is still 
a subject of debate. DA is synthesized in the cytosol and then uptaken into the 
pre ynaptic ve icles through vesicular monoamine transporter2 in an A TP­
dependent manner. Therefore, any decrease in ATP levels due to mitochondrial 
dysfunction will impair this mechanism inducing SN degeneration. Furthermore, 
DA metaboli m by itself generates ROS stress, making DA neurons more 
vulnerable to environmental toxins or mutations that increase DA turnover (S .  J. 
Lee, 2003). Put together, these facts suggest that mitochondrial dysfunction is a 
potential cause of PD. 
1.4 Aetioiog) of PD 
Despite the fact that PD was first diagnosed a century ago, till date the main 
causes for this disease remain undefined. All studies point to the involvement of 
both environmental and genetic factors in the etiology of PD. 
1 .4. 1 Gen etic facto rs 
6 
Tremendous progress toward understanding the genetic basis of PD has been 
achieved ill the past fifteen years. The first clue that genetic factors may be 
involved ill PD pathology came in the 1890s, when Gowers described the 
clustering of PD within families (Eadie, Scott, Lees, & Woodward, 2012; Gowers, 
1893). It is clear now that PD is a genetically heterogeneous disorder with at least 
28 distinct chromosomal regions involved. Familial PD accounts only for 10% of 
all PD cases (B. Thomas & Beal, 2007), and the remaining 90% is characterized as 
poradic PD. The aetiology of sporadic PD is still not clear, but it is thought to be 
triggered by the synergy of environmental and genetic factors. Familial PD can be 
cla sified a autosomal dominant and autosomal recessive. 
1.4. 1. 1 Autosomal dominant forms of PD 
1 . 4. 1. 2. 1  PARK1- S CA 
The a-syn gene, SNCA, coding for a-syn protein, was the first gene to be 
linked to autosomal dominant PD. It was first identified in a large ltalian­
American family with autosomal dominant early-onset PD, the Contursi kindred 
(Golbe, Oi Iorio, Bonavita, Miller, & Ouvoisin, 1990). The disease in this family 
locus was linked to chromosome 4q21-q23 and was later confirmed by the 
identification of a missense mutation, i.e. the replacement of alanine at position 53 
with threonine, (A53T), in ex on 4 of the gene (Po�ymeropoulos et aI., 1997). The 
same mutation was also found in three Greek families, who originate from the 
Peloponesos in Southern Greece (Polymeropoulos, et aI., 1997). The clinical and 
pathological features of the individuals with the A53T mutation in the SNCA are 
very similar to those with idiopathic PO, including a response to levodopa and the 
7 
presence of LBs in the S . However, PD in these individuals is associated with 
earlier onset, more severe phenotype and faster disease progression than that 
observed in patients with idiopathic PD (Fuchs et aI. , 2007· Ross et al. , 2008). 
A second missense mutation in exon 3 of SNCA, namely the replacement of 
alanine at po ition 30 with proline, (A30P), was found in a German family (KrUger 
et aL, 1998). In individuals with the A30P mutation, the age of onset of the disease 
is in their 50s, which is later compared to the age of onset of the disease in A53T 
indi idual . 
In 2004, a third point mutation was identified 111 a Spanish family. The 
replacement of glutamic acid at position 46 with lysine (E46K), has been 
as ociated with autosomal dominant PD (ZalTanz et aI., 2004). 
Two another novel missense mutations have been recently identified in this 
gene in PD patients. The first mutation was in exon 4 of SNCA encoding a 
histidine-to glutamine Substitution (H50Q) was identified in an English female 
patient at age 71 presented with tremor and was L-dopa responsi ve wi th negative 
family history (Proukakis et aI., 2013) and in a Canadian patient with positive 
family history for parkinsonism and dementia (Appel-Cresswell et aI., 2013). 
The second mutation was reported in a British family with early onset PD 
causing a glycine to aspartic acid amino acid change (G51D). Juvenile 
parkinsonism, moderate response to L-dopa and rapid disease progression with 
death in less than 10 years from onset mostly are the main symptoms associated 
. 
with G51D missense mutation (Kiely et al., 2013). 
8 
Duplications (Chartier-Harlin et al. , 2004; Ibanez et al., 2004) and 
triplications (A. B. Singleton, Farrer & Bonifati, 2013) of the a-syn gene have 
also been reported, and it is now understood that the severity of familial PD 
depends on S CA gene dosage and the a-syn expression levels (Ross, et al., 2008). 
This has led to the simple hypothesis of a dose relationship between a-synuclein 
levels and disease severity (A. Singleton & Gwinn-Hardy, 2004). 
I . 4. 1 . _. �  PARK5- UCH-LJ 
Ubiquitin carboxy-tenninal hydrolase-Ll (UCH-Ll); is a neuron-specific 
enzyn1 that cleaves carboxy-tem1inal peptide bond of polyubiquitine chain, thus 
uggesting a role as a ubiquitin-recycling enzyme (Leroy et al., 1998). Mutation of 
UCH-Ll was identified in a family of Gennan descent in which PD was inherited 
in an autosomal dominant fashion. The affected members had a missense mutation 
(I93M) in UCH-Ll that reduces its catalytic activity. In vitro this missense 
mutation cause various protein metabolites to aggregate (E. K. Tan & Skipper, 
2007). 
1 . 4. 1 . 2. 3  P ARK8- LRRK2 
Mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most corrunon 
known causes of autosomal dominant PD. LRRK2 was identified in a large 
Japanese pedigr�e, named the Sagamihara family, in which PD is inherited in an 
autosomal dominant fashion (Funayama et al. , 2002). So far seven mutation have 
been identified in LRRK2 (N1437H, R1441 C, R1441G, R1441H, Y1699C, 
G2019S, and 12020T) that are considered disease causing. G2019S is the most 
common mutation followed by R 1441 C. G2019S is very common among Arab 
9 
patients from orth Africa (Hulihan et a1., 2008) and Ashkenazi Jewish patients 
(Ozelius et a1. , 200 6 ). Degeneration of the dopaminergic neurons in the S and 
classical LBs are the common pathological features associated with LRRK2 
mutation (Zhu et al., 200 6 ). 
1 . 4.1 .2.4 PARK 1 7- Vacuolar protein sorting 35 (VPS35) 
In 2011 Farrer and colleagues identified a missense mutation in the VPS35 gene 
where aspartic acid was substituted with asparagine (D 620N), as a novel cause of 
autosomal dominant PO (Vilariiio-Giiell et aI., 2011). The mutation was reported 
in Swis kindred presented with late- onset PD. In the same year, the same 
missense mutation was reported in an Austrian family with 1 6  affected individuals 
with age of onset around 53 years (Zimprich et a1. , 2011). VPS35 is a component 
of the retromer complex and mediates retrograde transport between endosomes and 
the trans-Golgi network. The brain pathology in carriers of this mutation remains 
unknown. 
1 . 4. 1 . 2. 5  PARK 1 8- Eukwyotic translation initiation/actor 4 gamma 1 
(EIF4Gl) 
Missense mutation (R150 H) was identified in the EIF4G 1 ,  which is 
implicated in causing autosomal dominant PO by a genome-wide linkage approach 
in a large French family. Affected members of EIF4G I display with variable 
clinical and pathological symptoms that mostly resemble idiopathic, late-onset 
Lewy body PO (Chartier- Harlin et a!., 20 I I ) . 
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1.4. 1.2  A uto olt/al recessive, early-on et typical parkinsonism 
1 . 4. 1 .2. 1 PAR.K2- Parkin 
In 1998, Kitada et al. ,  was the first to describe the mutations in the newly 
identified gene parkin (P ARK2) that is associated with autosomal recessive early­
onset PD (Kitada et aI. , 1998). Since then, a number of mutations have been 
identified in PARK2 that account [or up to 10 % of early onset PD cases. The 
clinical ph notype of P ARK2 mutations is usually indistinguishable from early 
onset idiopathic PD, with slower response to levodopa and frequent late motor 
complications. It was thought that P ARK2 patients lack LBs and neurofibrillary 
tangle pathology; however a-syn immunopo itive inclusions existence in the 
pedunculopontine nucleus was reported in some recent studies (Farrer et aI., 2001; 
Gouider-Khouja et al., 2003; Mori et aI. , J 998' Pramstaller et aI., 2005). 
eurofibrillary tangles have also been reported in some cases with P ARK2 
mutations (Mori, et aI. , 1998). 
1. 4. 1 . 2. 2  PAR.K6- PINK1 
In 2001, Valente et aI. ,  reported linkage to chromosome 1p35-36 in a large 
Italian family, the Marsala kindred, in which PD was inherited in an autosomal 
recessive fashion. PINK 1 codes for a protein kinase that is localized in 
mitochondria and is related to cellular stress and response (Valente et aI., 2001). 
Studies of highly conserved Drosophila orthologs of parkin and PINK1 suggest 
that PINK l  and Parkin participate in a pathway that influences the integrity of 
flight muscle, sperm, and a subset of dopaminergic neurons in the brain. A 
prominent and an early feature in fly tissues is mitochondrial dysfunction linked to 
1 1  
Parkin and PINK l mutants (Clark et al. 200 6 ' Greene et ai., 2003). Hence the 
parkin and PINKl proteins are functionally linked. Together, they are important to 
tag damaged mitochondria for degradation by autophagy ( Narendra et al., 20 1 0). 
The clinical features of P INKl-linked parkinsonism include the typical signs of 
PD apart from an early age of onset (32-48 years), slow progression of symptoms 
and an early occurrence of Jevodopa-associated dyskinesia (Valente et ai., 2004). 
1 . 4. 1 . 2. 3  PARK7- DJ- 1 
PD patients with DJ- l mutation have an early onset between the ages of 20-40 
years. Although the function of DJ- l is still under investigation, however it has 
been proposed to play a protective role in the mitochondria by reducing oxidative 
tress generated during the inhibition of the electron transport chain (Abou­
Sleiman, Healy, Quinn, Lees, & Wood, 2003; Blackinton et ai., 2009; Canet­
Aviles et al. 2004; Trempe & Fon, 2013). It has been also implicated in multiple 
cellular processes, including oxidative stress response, protein quality control, anti­
apoptotic signaling, transcriptional regulation and translational control (da Costa, 
2007). Several studies have indicated that DJ-l may also be involved in other age­
related neurodegenerative disorders like Alzheimer disease ( Neumann et aI. ,  
2004). 
1.4. 1.3 A utosornal recessive, juvenile typical parkinsonism 
Several genes with recessive mutation were linked to very early onset 
(juvenile) PD with other clinical signs in addition to parkinsonism. P ARK9 ( 
Kufor-Rakeb syndrome), is characterized by juvenile, levodopa-responsive 
parkinsonism and dementia and is caused by recessive mutations in the ATPase 
1 2  
type 1 3A2 (ATP13A2) gene (Bras, Verloes Schneider, Mole, & Guerreiro, 2012), 
which encodes a lysosomal membrane transporter (Bras, et al. , 2012). 
Recessive mutations in PARK14 (Phospholipase A2, group VI (pLA2G 6 »  
gene were later identified in patients with levodopa-responsive parkinsonism 
pyramidal sign and cognitive features, with onset in early adulthood (paisan-Ruiz 
et al., 2012). Pathological analysis of brains of patients with PLA2G6 mutations 
revealed widespread LBs (Paisan-Ruiz, et aI., 20 12). 
Mutations in PARK15,  F-box only protein 7 gene (FBX07), also causes a 
r cessive fom1 of juvenile parkinsonism with pyramidal disturbances (T. Zhao et 
a I . ,  20 J 3). The brain pathology in patients with FBX07 mutations remains 
unknown. However, Zhao et at. ,  repOlted FBX07 immunoreactivity in the LBs of 
typical PD, and in glial cytoplasmic inclu ions of multiple system atrophy, 
uggesting an involvement of a-syn in the pathogenesis of the common forms of 
synucleinopathies (T. Zhao, et al., 20 13). 
During the past year, mutations in two other genes, DNAJC 6 and SYNJl ,  
',: ere identified as a rare cause of autosomal recessive, juvenile parkinsonism. 
D AJC 6 mutations were initially reported in a Palestinian family (Edvardson et 
al., 2012) and later in a Turkish family (Koroglu, Baysal, Cetinkaya, Karasoy, & 
Tolun, 20 13), while SYNJ l  mutation was identified independently in two families 
of Iranian and Italian origins (Krebs et aI., 2013; Quadri et al., 2013). Both genes 
are implicated to play roles in the post-endocytic recycling of synaptic vesicles. 








































































































































































































































































































































































































































































































































































































































































































































































































































































































1 .4.2 E n vi ro n mental  factors 
It was in 1877 that lean-Martin Charcot, a French neurologist known as ''the 
founder of modem neurology' pointed out that PD is not a family disease. Since 
then, there is accumulating evidence that exposure to some environmental agents 
contribute to the pathogenesis o[ PD. Experimental, epidemiological and animal 
m dels have helped in our understanding of the mechanisms through which these 
neurotoxicant act. 
1 . 4. _ . 1 MP TP (J . 4. 2. 1 . I -Methy-4-phyeny-I , 2, 3, 6-tetrahydropyridin) 
In order to claim that a certain toxicant is a potential risk factor for PD, 
expo ure to this toxicant should produce the well-known features that characterize 
PD. Unlike other environmental toxicants that can cause brain damage and result 
in symptoms that resemble PD, MPTP targets selectively the neurons involved in 
PD pathology. This makes MPTP one of most dangerous neurotoxicants but on the 
other hand, MPTP has been used to develop animal models that substantially 
helped in understanding the disease pathogenesis. The toxic effects of MPTP in 
PD pathogenesis was first discovered in 1983 when a group of drug abusers 
administered meperidine analogues contaminated with MPTP (CaIne & Langston, 
1983). The e individuals developed the typical clinical symptoms of parkinsonism 
and responded fairly to the treatment with levodopa (Ballard, Tetrud, & Langston, 
1985). Again Langston et ai. , in 1999 reported that examination of the brains of 
three self-administered drug abusers who developed Parkinsonism revealed 
moderate to severe depletion of pigmented nerve cells in the substantia nigra, thus 
building more evidence of the role of MPTP in idiopathic PD. Although LBs were 
1 5  
absent in the patients brains, the reason behind that was not clear (Langston et al., 
1999). MPTP is a lipid-soluble molecule which facilitates its penetration through 
the blood brain barrier. Once it enters the brain, MPTP is readily oxidized through 
MA O-B that is produced in astrocytes and serotonergic neurons into MPP+, the 
toxically active [onn of MPTP (Chiba, Trevor & Castagnoli, 1985). MPP+ is 
easily up-taken by the plasma membrane dopamine transporter (DAT) into the 
dopamin rgic neurons. Accumulation of MPP+ in the dopan1inergic neurons is the 
leading cause of the nigrostraital damage. This was further supported by the 
observation of Gainetdinov el aI. ,  that dopaminergic neurons lacking DA T are 
resistant to MPTP toxicity (Gainetdinov, Fumagalli, Jones, & Caron, 1997) while 
Sanghera et aI. ,  indicated that there is a positive correlation between DAT rnRNA 
levels and DA neurons susceptibility to MPTP (Sanghera, Manaye, McMahon, 
onsalla, & Gem1an, 1997). Within dopaminergic neurons, part of the MPP+ is 
taken through vesicular monoamine transporter 2 into the synaptic vesicles while 
the free MPP+ will ac umulate in the mitochondria. Free MPP+ that accumulates 
in the mitochondtia is the main player in triggering neurotoxicity. It has been 
proposed that trapping MPP
+ in the synaptic vesicles protects against MPP
+ 
toxicity and this hypothesis was further supported by the fact that vesicular 
monoamme transporter 2 heterozygote knockout mice showed a greater 
susceptibility to MPTP neurotoxicity (Takahashi et a!., 1997) . Free MPP
+ 
accumulated in the mitochondria leads to disruption of the respiratory chain by 
inhibiting complex I, resulting in two main cytotoxic consequences: decreased 
ATP production (Chiba, et aI., 1985) and increased ROS generation (Cleeter, 
Cooper, & Schapira, 1992). 
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1.4.2.2 Pe ticide . 
Clinical and experimental evidence has implicated the role of paraquat 
(bipyridyJ), organochlorine, organophosphate and roteniod compounds that are 
mainly found in pesticides and herbicides in the aetiology of PD. Epidemiological 
tudies have shown that individuals in the rural environments especially farming 
workers are at higher risks of developing PD. In 1987, Sanchez was the first to 
address paraquat a a neurotoxicant that contributes to PD pathogenesis (Sanchez­
Ramos, Hefti, & Weiner, 1987) and the fact that paraquat closely resembles MPTP 
in its chemical structure built a stronger evidence(Snyder & D'Amato, 1985). 
Interestingly, both in vitro and in vivo tudies showed that paraquat is capable of 
stimulating a-syn aggregation, a multi-step process that highlights the disease 
initiation and progres ion (Manning-Bog et ai . ,  2002). Other additional classes of 
pesticides that are to be considered as potential neurotoxicants are 
organophosphate and roteniod compounds. Rotenone is widely used in broad­
spectrwn pesticides and is a highly lipophilic compound that readily crosses the 
BBB. Similar to MPTP, rotenone is a classic complex I inhibitor, making it a 
potential mitochondrial poison. However, unlike MPTP, rotenone accumulates in 
the dopaminergic neurons independently of DAT (Uversky, 2004). 
1 .4. 2. 3  Heavy Metals. 
Although the exact etiology of PD is still to be convincingly established, 
many epidemiological studies reported that long term exposure to heavy metals 
like iron, manganese, copper mercury, lead and aluminum is a risk factor for. PD. 
Although exposure to these metals results in parkinsonian symptoms, however, 
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this doesn't  necessarily imply on the pathophysiology of the disease. Interestingly, 
patients exhibiting parkinsonism due to manganese exposure did not respond to L-
D OP A treatment and unlike idiopathic PD patients, midbrain region was not 
affected (Guilarte, 2010' Pal, Samii, & Calne, 1999). 
everal studies have shown that the level of iron is significantly elevated in 
the of PD patients. However, the link between iron accumulation and inducing 
PD pathology i not completely explained. It is hypothesized that iron acts on 
several levels causing dopaminergic degeneration in the SN .  Considering that iron 
is a redox-active metal, it is capable of catalyzing the formation of ROS inducing 
neuronal degeneration. As PO etiology involves the fibrilization of a-syn to form 
toxic aggregates, Uversky et aI. , demonstrated that low concentrations of some 
metals including iron, can directly facilitate a-syn aggregation (Uversky, Li, & 
Fink, 200 I b). 
1 . 4. 2. 4  Neuroprotective Agents. 
The first evidence on the existence of neuroprotective substances in the 
environment was illustrated by Baumann el at. , in study where he concluded that 
tobacco smokers are at lower risk of developing PD (Baumann, Jameson, McKean, 
Haack, & Weisberg, 1980). Consistent with this finding, further consecutive 
studies (for example, Grandinetti et al. " 1994; Hellenbrand et �l."  1997; Gorell el 
ai. " 1999) showed lower incidence of PD in tobacco smokers in a dose-dependent 
pattern. The first problem that scientists faced was in identifying which of the 
. 
tobacco constituents protect against neuronal damage knowing that tobacco 
contains hundreds of chemicals. The main focus was on nicotine that acted as a 
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neuroprotective but not neurorestorative agent ill animal models. More l ight 
remains to be shed on the mechanism by which n icotine prevents nigrostraital 
degeneration as that can great ly contribute to the development of novel therapies 
[or PD .  I t  has been suggested that nicotine action is mediated mainly through 
peci fic striatal n ictonic subtypes receptors that modulate dopamine release and 
thus dopaminergic neuron function (F. M. Zhou, Wi lson, & Oani ,  2002) .  Studies 
done on PO patients as wel l as animal models showed that nicotine is not able to 
improve the motor defic i ts associated with PO; rather it can halt disease 
progres ion ( Bordia, Campos, H uang, & Quik, 2008; Quik et al . ,  2007) .  In 20 1 3  
Quik et aI. , showed that further to nicotine's role in n igrostraitai prevention, it  can 
also redu e dyskinesia associated with long tem1 L-dopa treatment (Quik, Mallela, 
Ly, & Zhang, 20 1 3) .  More invest igation needs to  be  done about the role of  
nicotine as  a potential candidate in  developing therapeutic strategies for PD .  
Several recent studies provided an evidence that caffeine intake is associated 
with improvement in motor activity, through neuroprotection and neurorestoration 
by thropic proteins (Aj ravaara, Vouti lainen, Wang, & Hoffer, 20 1 2 ;  1. F .  Chen & 
Chern, 20 1 1 ;  Postuma et al . ,  2 0 1 2) .  In i tiating PO in  rats fol lowed by direct 
administration of caffeine after one week of disease onset prevented the loss of 
nigral dopaminergic neurons, i ndicating a rol e  for caffeine in delaying neuronal 
degeneration (Sonsal la et a l . ,  20 1 2) .  Moreover, caffeine has been shown to down 
regulate neuroin flammatory responses and nitric ox ide production, which protects 
against many pathological processes including cel l death (Salvemini, Kim, & 
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Moll ace  20 1 3 ; Tsutsui et al . ,  2004; Yadav Gupta, Srivastava, Srivastava, & 
S ingh, 20 1 2) .  
1 . 5  SYllucieill Family 
S ynuclein fami ly  has been under spotl ight for a long while now, since u-syn 
v a found to play a major role in PD pathogenesis and that mutated u-syn was 
associated with rare fami l ial cases of early-onset PD. In 1 988,  Maroteaux.et al 
was the fi rst to isolate and identi fy u-syn from Torpedo cali/arnica using anti­
serum again t puri fied chol inergic synaptic vesic l es. The name synuclein emerged 
from the protein localization; in the nuc lear envelope of the neurons and in the 
presynaptic nerve tenninals (Maroteaux, Campanel l i ,  & Schel ler, 1 988) .  
S ynucleins are smal l sol uble proteins highly expressed by neuronal cel ls .  
However, synuclein fami ly  is l ess expressed i n  other tissues such as heart, lung, 
P ancreas, Kidney and l iver ( Ltic et a l . ,  2004). Synuclein fami ly  consists of three 
distinc t  members that are exclusively produced in vertebrates: u- �- and y-syn. u­
Syn and �-syn are pri mari l y  expressed in the brain tissues while y-syn is primari ly  
found in  the peripheral nervous system and retina. u-Syn over-expression has been 
impl icated i n  neurodegenerative disorders such as PD, DLB and multiple system 
atrophy (MSA)'  however, y-syn over-expression is correlated with breast cancer 
progression (Bruening et a l . ,  2000) . On the structural level, all synucleins consist 
of highly conserved amino-teoninal domain where repetitive presence of the 
amino acid moti f KTKEGV is seen, and a less-conserved carboxy-teon inal domain 
that is rich in acidic residues. S ynucleins are natively unfolded proteins, meaning 
that under natural physiological conditions, these proteins have a l inear structure as 
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random coils .  Understanding the exact normal cel lu lar funct ion of this family  and 
i ts contribution to human diseases attracts the attention of many researchers. 
1 .5. 1 a-Syn 
a-Syn i a pre-synaptic neuronal protein and its aggregation and dysfunction 
I S  l inked to a number of neurodegenerati ve d isorders named as 
"synucleinopathies". Antibodi s against a-syn labeled both wapses and nuclei ,  
leading to the naming of  synuclein (Maroteaux, et a l . ,  1 988) .  Synucleinopathies 
main ly  refer to PD, dementia with Lewy bodies ( DLB) and MSA. a-Syn is 1 40 
amino-acid protein  that is bighly  abundant in the brain and can also be found in  red 
blood cel l  (Barbour et al . ,  2008),  plasma, cerebrospinal fluid (CSF) (EI-Agnaf et 
a l . ,  2003) and sal iva ( Devic et al . ,  20 1 1 ) .  a-Syn is encoded by SNeA gene, in 
which point mutations and gene mult ipl ications are ident ified in fami l ies with 
autosomal-dominant forms of P D  ( Hardy, Lewis, Revesz, Lees, & Paisan-Ruiz, 
2009) . The protein is natively unfolded; however it is  capable of fom1ing an a­
hel ical structure upon binding to negatively charged l ipids l ike cel l u lar 
phosphol ipids.  Structures rich in  �-sheets are formed as well under prolonged 
i ncubation of a-syn .  Three main domains define a-syn prote in :  ( 1 )  amino-terminus 
-tenn inal) that i nc ludes residues ( 1 -60) and are responsible for a-syn propensity 
to form a-helical structures (2)  the central hydrophobic region (NAC: non-A� 
component), which inc ludes residues (6 1 -95) and confers the �-sheet potential ,  (3 )  
a carboxy terminus (C-terminal) ,  which is  negatively charged and unl i ke NAC 
region,
' 
C-terminal is prone to stay unstructured (Hoyer, Cherny, Subramaniam, & 
lovin, 2004; Maroteaux & Schel ler, 1 99 1 )  (Fig.  1 .2) .  
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The precise function of  this protein and the mechan ism by which i t  provokes 
neuronal cel l death is not ful l y  understood. Several l ines of evidence through 
studies on di fferent model organisms, suggest that a-syn is a major player 10 
vesic le  trafficking synaptic plastici ty and neurotransmitter release. 
Abeliovich el aI. , showed in his study using a-syn knockout mice, that a-syn 
deficiency did not comprise the DA neuronal morphology, uggesting that a-syn is 
neither es ential for neuronal development nor for pre-synaptic terminals 
development. On the other hand, mice exhibited an increase of DA release at 
n igro traital tenninals in response to e lectrical paired stimu l i  and a reduction in 
striatal DA content, suggesting that a-syn is an essential, act ivity-dependent 
negative regul ator of DA neurotransmission (Abel iovich et aI . ,  2000).  
I t  is  well  known that lack of  the synaptic co-chaperone cysteine-string protein 
alpha (C Pa) resu lts in a severe progressive neurodegeneration, but an interesting 
observation was that transgenic expressIOn of a-syn amel iorated the 
neurodegeneration and the motor impainnent seen 10 CSPa knockout mIce. 
Chandra el a/. ,  also showed that transgenic a-syn expression helps reverse the 
inh ibit ion of SNARE complex assembly due to CSPa deletion (Chandra, Gal lardo, 
Fernandez-Chacon, Schluter, & Slidhof, 2005) .  Hereby, there is a growing body of 
knowledge that a-syn has a physiological role as natural neuroprotective protein at 
the synapse. 
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1 .5.2 P-Syn 
Another member of synuclein family is �-syn (Phosphoneuroprotein- 1 4  PNP-
1 4) ,  encoded by SNCB gene, and located at chromosome 5. �-Syn is a 1 34 amino 
acid protein haring 78% homology with a-syn (Beyer et aI . ,  20 1 0). Simi lar to a-
yn, �-syn is  a nativ ly unfolded protein that co- localize in presynaptic terminals 
( M aroteaux et a l . ,  1 988) .  Unl ike a-syn, it lack 1 1  hydrophobic amino acid 
r sidu s in its central region that correspond to the 72-84 residues of a-syn,  
re u l ting in  non-amyloidgenic homologue of a-syn ( Fig. 1 .2). There is a growing 
e idence that �- yn can be a natural i nhibitor for a-syn aggregation. Rockenstein 
(!/ aI. ,  pointed out that a critical balance in the rat io of �-syn to a-syn should be 
maintained for the normal function of the brain and that this ratio is altered in DLB 
pat ients ( Rocken tein et a1 . ,  200 1 ) . Whi le wild t pe �-syn fai l s  to fibri l ize, mutant 
�-syn where AC domain is added was able to confer aggregation properties 
simi lar to a-syn (Hashimoto, Rockenstein, Mante, Mal lory, & Masl iah, 200 1 ) . 
These results were consistent with another study where �-syn was exposed to 
assembly conditions for 6 weeks but sti l l  did not polymerize ascertaining the 
i mportance of the hydrophobic region for the protein aggregation (Giasson, 
Murray, Troj anowski , & Lee, 200 1 ) . Behavioral assessment of transgenic (tg) mice 
expressing h uman a-syn solely and tg mice co-expressing human a-syn and human 
�-syn supported the idea that �-syn can act as a natural negative regulator for a-syn 
aggregation (Hashimoto, et al . ,  200 1 ) . Whi le  motor dysfunction was c learly seen 
in tg mice expressing human a-syn only, s ignificant amel ioration was observed in 
tg m ice co-expressing human a-syn and human �-syn (Hashimoto, et aI . ,  200 1 ) . 
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F urthermore, fewer pathological inclusions were seen i n  bigenic rrllce compared to 
human Cl-Syn tg mice. As a further confirmation, cel ls over expressing human Cl­
syn and transfected with p-syn didn' t  display any inclusions suggest ing that p-syn 
can block Cl- yn aggregation ( Hashimoto, et aI . ,  200 1 ) . Taken together these 
studie suggest the possibil ity of using the non-amyloidgenic properties of �-syn i n  
d e  eloping novel treatments for PD. 
1 .5.3 y-Syn 
Unl ike Cl- yn, y-syn is not c learly involved in neurodegenerative diseases. 
Howe er, y-syn ha been impl icated in advanced breast carcinomas (Wu et aI . ,  
2007) and other mal ignancies, including oVaIian (Bruening, et aI . ,  2000), gastric 
(Yanagawa et a I . ,  2004), esophagus (c. Q. Zhou et aI . ,  2003) , l iver (W. Zhao et 
aI . ,  2006) , and pancreatic (H ib i  et aI . ,  2009) CaI1CerS . The y-syn gene, SNCG, is 
located on c hromosome 1 0q23 and encodes a 1 27 anlino acid protein. ')'-syn gene 
which is also known as ' Breast cancer -speci fic gene 1 "  (BCSG 1 ), is barely 
present in n0l111al or benign breast lesions, whereas it is highly abundaIlt in 
advanced infil trating breast cancers suggesting that BCSGl can be useful as a 
marker of  breast c ancer progression (J i  et aI . ,  1 997) .  The highest homology 
between this protein and the other two members of this fami ly  is seen in the 
aI11 ino-terminal region ( Fig. 1 .2) .  Several stud ies howed that ')'-syn has a di fferent 
pattern of expression; it is expressed in  the early stages of axonal outgrowth and 
mai ntained throughout l i fe, suggest ing that ')'-syn is important for maintaining the 
integrity of  the neuro fi lanlent network (Buchman et aI . ,  1 998). Unl ike Cl-syn, ')'-syn 
has a weak tendency to form amyloid fibri ls  (Giasson, et al . 200 1 ). 
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Fig. 1 .2 The human synuc1ein family. 
[he bars repre ent the different types of synuclein . The different amino acid 
residue are represented at the bottom. The -temunal (amphipathic region), the 
hydrophobic C domain and the C-terminal (hydrophilic acidic tail) are 
separated by vertical dashe and clearly indicated by different colors. The 
percentage under each domain represent the degree of amino acid identity as 
compared to a-syn. 
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1. 6 a-SYIl post-trallslational modifications 
a- y11 is ubj ected to several po t-translational modifications uch as 
pho phorylation, oxidation, nitrosylation, truncation and ubiquitination. However, 
whether these po t-tran lational modifications act to enhance or inhibit a-syn 
neurotoxicity remains to be understood. A better understanding of the role of a-syn 
post-translational modifications will help to elucidate the exact role of a-syn in 
the pathogenesis of PO, pa ing the way to develop new diagnostic and therapeutic 
strategie for synucl einopathies. Although al l these modification have been 
studied. the main attention i focused on phosphorylation. Iwatsubo and colleagues 
presented the fi rst e idence of a- yn phosphorylation at Serl 29 through 
immunohi tochemical and biochenucal studies which was later supported by oth
er 
studies. Antibodies generated specifically against S I 29-phosphoryl ated a-syn (p-
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S 1 29-a-syn), were able to stain LBs from bralns of patients who died with P D, 
MSA or DLB (Anderson et al .  2006; Fuj iwara et a1 . ,  2002; Okochi et a1 . ,  2000). 
Other studies demonstrated that a-syn can be phosphorylated at mUltiple sites. 
Pal o log u el aI. ,  showed that a-syn is phosphorylated at Ser87 in vivo and in LBs 
in synuc leinopathies (Paleologou et aI . ,  20 1 0),  while Feany and his col leagues 
proved that a-syn can also be phosphorylated at Tyr 1 25 (L .  Chen et aI . ,  2009) . 
In  human brains, 90% of  total a-syn found in LBs is phosphorylated at 
er 1 29, rais ing an important quest ion whether a-syn phosphorylation promotes or 
protects against neurotoxic ity? Some studies reported that over-expression of 
PLKs, which pho phorylates a-syn spec i fical ly  at  Ser 1 29, in the nematode (C. 
e legnas) suppressed neurotoxic ity and protected against dopaminergic cel l loss 
( Kuwahara, Tonegawa, I to, Mitani, & Iwatsubo, 20 1 2) .  In rat model s, where 
1 29A or S 1 29D mutation ware induced, which mimics the absence of  
pho phorylation or  mimics the phosphorylation repectively, an  increase in  a-syn 
toxic i ty through up-regulation of  beta-sheet rich, proteinase-K resistant aggregates 
formation was observed ( Gorbatyuk et aI . ,  2008) .  More findings that support the 
hypothesis that phosphorylation of a-syn is  protective Mbefo et at. , showed that 
P LK2, which is a member of Polo-Like Kinases and a major contributor to a-syn 
phosphorylation, is protective against a-syn toxici ty in vitro and in vivo (Mbefo et 
a I . ,  20 1 0) .  On the other hand Chen et aI. ,  showed in transgenic drosoph i la model s  
that phosphorylation a t  Ser 1 29 i s  a crucial step in  enhanc ing a-syn neurotoxicity 
through the formation of a-syn soluble o l igomers but not a-syn mature inclusions 
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( L. Chen & Feany, 2 005) .  Others reported that phosphorylat ion of a-syn has no 
effect on neurotoxicity (Azeredo da Si lveira et al . ,  2009; McFarland et al., 2009). 
B iochemical examination of LBs revealed the presence of ful l - length a-syn as 
well a di fferent specie of truncated a-syn wi th molecular weight ranging from 
1 O- 1 5 kDa (Anderson, et a1 . ,  2006 · Baba et ai . ,  1 998) .  Interest ingly, truncated a-syn 
wa found in the brains of patients as wel l  as the brains of healthy controls, 
uggest ing that a-syn truncation takes p lace even under normal physiological 
conditions. I nterestingl y, a marked di fference in the amount of truncated a-syn in 
ynucleinopathies patients compared to controls was found (Beyer et a1., 2004). 
Beyer et a ! .  howed that there was a twofold increase in truncated a-syn expression 
in DLB compared to controls, and a threefold increase in DLB compared to AD 
patients (Beyer, et a i . ,  2004) .  Truncated a-syn was found to be abundant in the 
brain of PD and DLB patients suggest ing that truncated a-syn may play a normal 
physiological rol e  as wel l  as a pathological one CW.  Li et aI . ,  2005). SH-SY5Y 
cel ls exhibited more vu lnerabi l ity to oxidative stress when full  length a-syn and 
truncated a-syn were co-overexpressed (Liu et aI . ,  2005). Accumulation of 
truncated a-syn was signi ficantly high in the brains of tg mice expressing human 
A53T mutation which is  found in  some c ases of fami l ial P D  and l inked to early 
on et of  the disease ( Michel l et aI . ,  2007). Taken al l  together, these data suggest 
that a-syn truncation forms highly amyloidgenic fragments that accelerate or seed 
a-syn aggregation . Light was most ly shed on C-terminal truncated a-syn as it 
exhibited a h igher propensity to fibri l ize in  comparison with WT ful l  length a-syn .  
Extensive research was done in  this area that supported this hypothesis. Hoyer el 
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aI. , reported by in vitro studies that truncated a-syn specifically C-terminal 
residues 1 09- 1 40 promoted aggregation presumably through nucleation formation 
( Hoyer, et aI . ,  2004) .  
I mm unohi tochemical studies have shown that tyrosine nitration in  LBs is  a 
common feature of  synuc !einopathies ( Dekker Abel lo, W isastra, & B ischoff, 
2 0 1 2) . Giasson et al. , was the fir t to provide a strong evidence of n itrated a-syn 
a cumulation in LBs via the use of spec ific monoclonal antibodies for the nitrated 
fOIm of  a- yn, demonstrating that nitration affects a-syn solubi l i ty and promotes 
it aggregation (Gias on et a1 . ,  2000) . 
1. 7 a.-S)'1l Aggregation 
The findings that (a) fibri l l ar a-syn is the major component of L Bs, and (b) 
the A30P, E46K and A53T forms of a- yn, which are associated with autosomal 
dominantly inheri ted forms of PO, have higher rates of sel f-ol igomerization 
compared to WT a-syn (EI -Agnaf Curran, et aI . ,  1 998;  Zarranz, et a1 . ,  2004) have 
l ed to the speculation that the aggregat ion of a -syn has a seminal role  in PD.  As a 
result  extensive efforts have been put into the elucidation of the mechanisms 
responsib le  for the polymerization and aggregat ion of a-syn. 
In v i tro stud ies have shown that a-syn, the wt and the A53T, A30P and E46K 
m utated forms, are able  to sel f-aggregate and fonn fibri ls  which structural ly 
resemble  those i solated from LBs and LNs (EI-Agnaf, Curran, et a1 . ,  1 998;  
Zarranz, et  aI . ,  2004). I nterestingl y, the mutated forms of a-syn, especial ly the 
ones with the A53T and E46K mutations (Conway, Harper, & Lansbury, 1 998;  EI-
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Agnaf Curran et aI., 1 998;  Zarranz, et a1 .  2004), were shown to have h igher 
aggregation rates, possibly because these mutations di srupt the a-helical structure 
o f  the protein i n  the N-terrninal region. In fact, studies done on aged a-syn 
s lutions have demon trated that the aggregation of the protein is accompanied by 
a confonnat ional transition from random coil or a-hel ical structure to cross p_ 
p leated sheet ( EI-Agnaf, Jakes, et aI . ,  1 998 ;  Serpel l ,  Berriman, Jakes, Goedert, & 
rowther, 2000) .  
T h e  fi bri l lation proce o f  a-syn has been suggested to occur via ol igomers 
and th n protofibri l fonnation, which in tum associate to produce mature filaments 
(Conway, et aI . ,  1 998) .  a-Syn aggregation is a nuc leation dependent process and 
this proce s can be divided into three phases ( Wood et a1 . ,  1 999): 
I .  I n itial phase dUIing which the nuclei are fonned. 
2 .  Elongation phase, characterized by the exponential growth o f  the fibri ls. 
3. The Equ i l ibrium phase, during which the protein in solution is  equi l ibrium with 
the protein in fibri l l ar fonn ( Uversky et a!. 2002). This phase is associated with a 
dramatic confonnational change from random coil  to predom inant ly p-pleated 
sheet (Conway, H arper, & Lansbury, 2000). The p-sheets then proceeds through 
the fonnation o f  several altered-sized ol igomers to fonn protofibri l s  ( intennediate 
stage) before maturing into long strands and then LBs (Goldberg & Lansbury, 
2000) . It has been shown that the fibri l l ation rate is concentration dependent, 
i ncreasing with higher protein concentration and pH-dependent, increa.,sing by a 
decrease in pH (Uversky, Li, & Fink, 200 1 a), temperature dependent, increasing 
29 
with i ncreasing temperature (Hashimoto et aI . ,  1 998) and the presence of  metals 
( Kanda, B ishop Egl i ti s, Yang, & Mouradian, 2000) .  
1. 8 a-Syn Aggregation and Toxicity 
As described above, there are numerous findings suggesting that a-syn 
aggregation plays a central role  in the pathogenesis of synucleinopathies. First, the 
main comp nenls of LB are filaments of a-syn (Spi l l antin i ,  et aI . ,  1 998) and in 
vitro studies ha e shown that recombinant a-syn can form inc lusions that resemble 
L B  ( H ashimoto, et  aI . ,  1 998;  arhi et  a1 .  1 999) .  
Second, five missense a-syn mutations (see also section 1 .4. 1 )  have been 
l inked to rare fOlm of early-onset fami l ial PO (Appel-Cresswel l ,  et a 1 . ,  20 1 3 ; 
Kriiger, et a1 . ,  1 998 ;  Polymeropoulos, et aI . ,  1 997; Proukakis, et aI . ,  20 1 3 ; Zarranz, 
et al . ,  2004), and they have been shown to increase a-syn aggregation in vitro 
( Conway, et a 1 . ,  2000; EI-Agnaf, Curran, et a1 . ,  1 998;  Narhi ,  et a1 .  1 999). I t  has 
been shown that m utant a-syn contain more �-sheet structure than the wt protein 
(EI-Agnaf, Jakes, et a l . ,  1 998) .  Third,  oxidative damage to a-syn makes the protein 
more prone to aggregation (Esteves, Arduino, Swerdlow, Oliveira, & Cardoso, 
2009' Kanda, et a1 .  2000) .  
I n  an effort to  elucidate the toxic effect of the aggregated forms of a-syn on 
d i fferent ce l l  l ines i n  vitro, EI-Agnaf e t  aI. ,  reported 'that fresh and aged NAC ( 1 -
1 8) and AC ( 1 -3 5 )  added direct ly to c ultures of SH-SY5Y cel l s  were toxic, with 
the aged AC being more toxic  than the fresh, sug�esting that the cytotoxici ty is  
aggregation-dependent (E l -Agnaf, Jakes, et a1 . ,  1 998) .  
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In vitro studies on the effect of a-syn overexpression have been carried out 
using EK293 and SK-N-SH cells .  Overexpressing a-syn induced toxicity in both 
cel l l ines in  a dose-dependent manner and the mutations (A53T and A30P) 
increased cell toxic i t  ; however, the A53T mutant a-syn form was more toxic to 
th cell  (Ostrerova et al . ,  1 999).  
Toxic  effects of aggregated a-syn were observed in many conducted in vivo 
tudies. For example, Masl iah and co-workers have used transgenic  mice 
o erexpre sing human a-syn .  Their results showed loss of dopaminergic teI111inals 
in  the basal gangl ia in addition to motor impairments. Moreover, formation of both 
cytop lasmic inclusions and electron-dense intranuclear deposits was seen through 
ul trastructural analysis. These inclusions were composed of granular aggregated a-
syn ( M as l iah et al . ,  2000). 
Furthermore, many studies have shown that overexpression of human a-syn in 
transgenic fl ies and mice is accompanied by neuronal dysfunction and loss of 
synaptic tem1inals and/or neurons and the fonnation of lesions similar to those 
found in PD brain (Feany & Bender, 2000; Kahle, Neumann, Ozmen, & Haass, 
2000; M artin, 2007 ; Mart in et al . ,  2006; Mizuno, Fuj ikake Wad a, & Nagai, 20 1 0; 
S iebert et al . ,  20 1 0; van der Putt en et al . ,  2000). These animals, also, progressively 
develop motor abnomlal it ies. 
M any recent findings support the not ion that a-syn spreads in a prion-l ike 
fashion, playing a cruc ial ro le in 
.
PD propagation and pathogenesis. a-Syn was 
thought first to be an exclusively intracel lular prote in, however the detection of a-
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syn i n  biological fluids such as b lood plasma and CSF has chal lenged this idea 
( Borghi et al . ,  2000; EI -Agnaf, Salem, et al " 2003) .  I t  has been found that (l-syn is  
released in the  culture medium of neuronal cel l s  under normal or  induced 
expression (Danzer et a i . ,  20 1 1 ;  EI-Agnaf, Salem, et aI . ,  2003;  Emmanoui l idou et 
a l .  20 1 0; H .  J. Lee, Patel, & Lee 2005 ; Sung et aI . ,  2005) but whether released (l­
syn has physiological [unction is sti l l  unknown . This hypothesis was supported by 
the discovery that PD patients subjected to striatal mesencephal ic grafts 
transplantation, developed (l-syn-positive and ubiquitin-positive LBs decade 
fol lowing transplantation ( Kordower Chu, Hauser, Freeman, & Olanow, 2008 ; J .  
Y .  Li  et a I . ,  2008) 
The mechanism of (l-syn release has not been ful ly  elucidated. Lee and 
col leagues howed that a portion of intracel l ular a-syn is constitutively secreted to 
the culture medium via endoplasmic reticulum/Golgi-independent exocytosis (H .  J .  
Lee, et  ai . ,  2005) .  When appl ied to cultured neuronal cells, both ol igomeric and 
fibri l lar fonns of a-syn were internal ized via endocytosis and degraded by the 
lysosome (H .  1 .  Lee et aI . ,  2008).  
I t  has been proposed that a-syn is  directl y  transmitted from one cel l to another 
via sequential exocytosis and endocytosis, forming Lewy-l ike inclusions in 
rec ipient cel ls  (Desplats et aI . ,  2009) . Emmanouil idou et aI. ,  used an inducible 
neuroblastoma cel l l i ne that expresses a-syn and found that (l-syn is  secreted from 
neuronal cel l s  in a calcium-dependent manner by exosomes and that soluble 
ol igomeric and monomeric a-syn species were released in association with 
externalized membrane vesic les ( Emmanouil idou, et a I . ,  20 1 0) .  
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Cel l to cel l transmission has been also demonstrated in vivo. Desplats et at. , 
showed that inj ection o f  mouse cortical neuronal stem cell s  in the hippocampus of 
transgenic mice overe pressing human a-syn, resulted in transfer of a-syn species 
from host neurons to grafted cel l s  ( Desplats, et aI . ,  2009) .  
Han en e t  of. . demonstrated that neurons can internal ize a-syn specIes 
regardless i ts aggregation state and that the aggregated form structure is conserved 
throughout the internal ization process (Hansen et aI . ,  20 1 1 ) .  Furthermore, in the 
same study, transplantation of wt mouse embryonic mesencephal ic grafts into the 
triatum of tg mice overexpress ing human a-syn, has led to a-syn transmission 
from the host striatal tissue to the transplanted dopaminergic neurons (Hansen, et 
a1 . , 20 1 l ) .  
V irg inia Lee and col leagues showed that a-syn cel l -to-cel l  transmission 
occurred after a single i ntrastriatal inoculation of synthet ic a-syn fibri ls in non­
tran genic mice and that Parkinson's- l ike Lewy pathology was seen in 
anatomical l y  interconnected regions (Luk et a1 . 20 1 2) .  
1. 9 A nimal Models of PD 
To acquire a better understanding of P D  pathogenesis and to develop better 
disease modifying therapeutic strategies, PD animal models can be of great 
assistance. The l ast two decades have witnessed a marked improvement in 
developing mult iple models of PD with different mechanisms of insult. Modeling 
PD can be quite a chal lenge, as the "reasonable" model should be able to 
;ecapitulate the c l inical and pathological features of PD (Chesselet, F leming, 
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Mortazavi & Meurers 2008) .  PD models should develop dopaminergic 
degeneration progressively and age-dependently as PD begins mostly in late 
adulthood. Another major obstacle is that they should be able to reproduce the 
motor symptoms of PD l ike bradykine ia, rigidity and resting tremor and they 
should respond to DA replacement therapy as wel l .  Among the widely used animal 
models of PD pathogen ic and etiologic models are the most common. Pathogenic 
model refer to the ones where DA depletion was induced through neurotoxins l ike 
reserpine M PTP, rotenone and paraquat. Etiologic models are also known as 
disease gene-based models .  They mimic PD by expressing specific mutations in 
gene associated with fami l ial fonns or PD.  
1 .9 . 1  N e u rotox i n  m odels 
I t  was in 1 970s that Ungerstedt reported the first model of PD in rats produced 
by an intracerebral injection of 6-hydroxydopamine (6-0H DA) (Ungerstedt & 
Arbuthnott, 1 970) . 6-0HD A  was first isolated i n  1 950s and it affects the dopamine 
transport system and disrupts the electron transport chain of  complex I in the 
mitochondria. It does not cross the blood brain barrier (BBB), which necessitates 
its d irect injection into substantia nigra, medial forebrain bundle, and striatum 
( Perese, U l man, Viola, Ewing, & Bankiewicz, 1 989; 1. Thomas et al . ,  1 994) . 
Although it causes a progressive neuronal degeneration in the substantia nigra and 
ventral tegmental complex, no LBs are fonned (Berger, Przedborski, & Cadet, 
1 99 1 ;  Sauer & Oertel ,  1 994). 6-0HDA is mainly used to Screen for therapies that 
may improve PD symptoms and to study cell  death mechanisms. Ten years later, a 
group of  young drug addicts displayed c l inical symptoms that greatly resembled 
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P D  due to administration of heroin analogous contaminated by MPTP, which 
triggered the researchers curiosity to test this compound in different animal 
species. MPTP administration was capable of reproducing most of the PD c l inical 
and pathological feature in monkey (Chiueh et al . ,  1 984; Crossman, Mitchell ,  & 
ambrook, 1 98 5 '  Doudet, Gross Lebrun-Grandie, & Bioulac, 1 985 ;  Heikki la, 
H e  s, & Duvoisin, 1 984, 1 98 5 ;  Langston Forno, Rebert, & I rwin, 1 984; Nomoto, 
Jenn r, & Mar den, 1 98 5 )  and whi le dopaminergic degeneration was obviously 
een in mice, rats showed resistance to M PTP effects (Chiueh, et aI . ,  1 984). MPTP 
model produces PD feature by the same mechanism as 6-0HDA. The main 
advantage of M PTP model is that MPP+ selectively damages dopaminergic 
neuron . MPTP is highly l ipophi l ic, thus it readi ly cros es the BBB after systemic 
administration. Subcutaneous and intravenous are the most common routes of 
administration (przedborski et  aL , 200 1 )  whi le unilateral intracarotid i njection is  
us d when only uni lateral parkinsonism in required (Bankiewicz et  a I . ,  1 986) .  I n  
M PTP models, loss of  DA neurons is dose dependent and inclusions are rarely 
seen, however J in  et al. , reported that combining M PTP with proenec id (a 
pesticide) induces the formation of L Bs-l i ke (Jin et aI . ,  2005) .  
Rotenone is a pestic ide that is able to di ffuse through all cel lu lar membranes 
i ncluding the BBB.  It strongly inhibits complex I in the electron transfer chain, 
l eading main ly to nigrostraital dopaminergic degeneration with a-syn positive 
inclusions simi lar to true LBs (Betarbet et aL, 2000; Sherer, Kim, Betarbet, & 
Greenamyre, 2003 ;  Testa, Sherer, & Greenamyre, 2005 ) .  
Paraquat is a herbicide simi lar to MPTP that crosses the BBB and destroy 
dopaminergic neurons in the substantia nigra. Paraquat is associated with the 
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[ormation of a-syn positive inclusion in  the substantia nigra pars compacta over 
prolonged exposure (Brooks, Chadwick, Gelbard, Cory-Slechta, & Federoff, 1999; 
Mann ing-Bog, et al .  2002). 
1 .9 .2  T ra nsgenic  A n i m a l  fo r PD 
Genetic an imal modcls of  PD were developed main ly to overcome the flaws 
seen wi th the c lassical tox in-based models. Genetic mutations in PD represent only 
about 1 0% o[ al l  PD case · however gene-based models can be very instructive in 
understanding not only PD pathogene i but other neurodegenerat ive disea es as 
wel l .  
The developed animal models succeeded in exhibit ing most PD features l i ke 
neuronal l oss, neuropathology, neurochemical al teration and motor defici ts ( for 
detai ls  see above section 1 .8 ) .  
1. 10 a-Syn: a potelltial biomarker for PD 
everal recent stud ies have explored the use of  a-syn as a potential PD 
biomarker in human biological flu ids. a-Syn was fi rst detected in CSF using 
immulloprec ip itation and immulloblotting with a - syn specific antibodies ( Borghi ,  
e t  a l . ,  2000; EI -Agnaf, Salem, et  aI . ,  2003 ) .  Several studies have in estigated the 
levels of total a-syn (t-a-syn) in CSF as measured with ELISA, but results were 
not conc lusive. Some studies have shown a c lear trend of lower CSF t-a-syn in PD 
and other synucleinopathies such as MSA and DLB ( Hong et aI . ,  20 1 0; 
Mol lenhauer et a l . ,  2008; Mol lenhauer et aI . ,  2 0 1 1 ;  Tateno, Sakakibara, Kawai, 
Kishi ,  & M urano, 20 1 2; Tokuda et al . ,  2006). On the other hand, a large overlap in  
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t-a-syn was observed between PD and other disease (Aerts, Esselink, Abdo, 
B loem, & Verbeek, 20 1 2; oguchi-Shinohara et a1 . ,  2009; Ohrfelt et a1 . ,  2009; 
Pametti et a1 . ,  20 1 1 ) .  Col lectively, these studies suggest that the use of t-a-syn 
alone as CSF biomarker [or PD is not enough. Many factors might contribute to 
i nconsistency between the groups including variabi l i ty in patients' characteristics, 
uch as age, disea e duration and disease severi ty. The discordance of the reported 
re ult might also be caused by methodological issues, including pre-analytical 
di ffer nces in col lection, h andl ing and storage of CSF samples, use of d ifferent 
antibodies that detect di fferent species of a-syn, and variabi l i ty among sources of 
recombinant a-syn protein used as the standard in the EL ISA assays. Another 
c rit ical factor is represented by blood contami nation, which could cause substantial 
increa es in C F a-syn concentration (Hong, et aI . ,  20 1 0) .  
Sub tantial evidence suggests that soluble ol igomers of amyloid proteins play 
a crucial role i n  the pathogenesis of neurodegenerative diseases. Several recent 
tud ies showed that CL-syn o l igomers (o-a-syn)  are neurotoxic in vitro and in vivo 
(Winner et aI . ,  20 1 1 ·  Xu et a1 . ,  2002) .  Paleologou et at. ,  reported that the levels of 
o-a-syn are elevated in brain homogenates in PD and DLB compared with normal 
brains suggesting a role for o-a-syn in PD pathogenesis ( Paleologou et a1 . ,  2009) .  
Accordingly, detection of these species i n  CSF could represent a good biomarker 
of PD and related synucleinopathies (E I -Agnaf, Walsh, & Al lsop, 2003) .  In 20 1 0, 
E I -Agnaf and colleagues found that o-a-syn levels and o-a-syn: t-a-syn ratios were 
substantially h igher i n  patients with PD including those with mild and early-stage 
d isease than i n  i ndiv iduals with other neurological disorders, or those who 
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underwent l umbar puncture for diagnostic purposes (Tokuda et al . ,  20 1 0) .  CSF 0-
a-syn had a sensit ivity 0[ 75.0% and a specificity of 87.5% for PD, and the CSF 0-
a-syn: t-a-syn ratio had a sensit ivity of 89.3% and a spec ificity of 90.6%. These 
findings have been confirmed in two independent reports (park, Cheon, Bae, Kim, 
& Kim, 20 1 1 ;  ierks et a1 . 20 1 1 ) .  
L B s  are formed mostly o f  post-translat ional ly modi fied forms o f  a-syn. The 
modifications inc lude phosphorylation, n itration and ubiquit ination, and most of 
the accumulated a-syn in  Lewy bodies i s  phosphorylated at Ser 1 29 (pS 1 29-a-syn) . 
Whether p I 29-a-syn promotes or protects against PD is  unclear however, pS 1 29 
a-syn level can improve discrimination between P D  and oU1er forms of 
parkinsonism ( Wang et  a i . ,  20 1 2 ) .  
1. 1 1  Objectives of the Project 
Taken together, al l  of the genetic, pathological, b iochemical and animal 
model data support the idea that a-syn aggregation p lays a critical role in  
syn uc leinopathies. Therefore, developing methods that can detect the pathogenic 
fonns of  a-syn may provide d iagnostic  tools  for an early diagnosis of PD. The aim 
of  the proj ect was to develop new immunoassays for measuring t-a-syn, o-a-syn 
and p-S 1 29-a-syn pec ies in  human CSF as potential biomarkers for PD to provide 
an early d iagnosis, monitor disease progression and demonstrate treatment 
efficacy. 
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C H APT E R  T W O :  M a teria ls  
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2. 1 
2.1 Suppliers 
Detai ls  of the suppl iers o f  chemicals and equipment used are summarized i n  table 
arne and location of suppliers of chemicals and equipment 
Igma 
BD Biosciencese 













Full Name and Location 
Abcam Inc. Kendall Square, Cambridge, UK. 
S igma-Aldrich Co. Ltd.,  Dorset, UK. 
B ecton, Dickinson and Company, Franklin Lakes, 
USA. 
G i l son, Inc.3000 Pannenter Street, Middleton, 
WI ,  USA. 
Invitrogen Corporation, 579 1 Van Allen Way 
Carlsbad, CA 92008, USA 
Nalgene, unc International,  Life Technologies 
Ltd. , Paisley, UK. 
Thenno Scient ific Life Science Research 
Products, Rockford, IL, USA. 
Santa Cruz Biotechnology, Delaware Avenue, 
Santa Cruz, CA, U.S .A. 
Jackson ImmunoResearch, UK 
Immuno-BiologicaJ Laboratories Co. ,  Ltd, Japan 
M erck Mi l l ipore, Bi l lerica, Massachusetts 
SeraCare K irkegaard & Perry Laboratories, 
Maryland, USA 
M erck Sharp & Dohme, USA 
G ibco, Life technologies, New York, USA 
Hyclone, Life technologies, New York, USA 
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2. 2 Material and equipments 
Detai ls  of the chemicals and equipment used are summarized in table 2 .2 .  
T a b l e  2 . 2 :  Summary of chemicals/equipments 
MaterialsfEquipment 
Albumin from bovine serum :::0:98% 
(agarose gel electrophoresis) 
B A Protein assay reagent kit 
Bovine serum Albumin 
CDM4mAb Media 
eUytic M cell lysis reagent for 
cultured mammal ian cel ls  
Dimethyl sulfoxide (DM 0) 
Ethylcnediaminetetraacetic acid  (EDT A) 
Fetal bovi ne serum 
Glutamax 
Gultamax 
HAT Media Suppliment (SOX) Hybri -Max 
HT Media Suppliment (SOX) Hybri -Max 
lscovemod Dulbecco ( I MDM) 
Isotyping Ki t 
Maxi Sorpnt 384 wel l  black plates 
MaxiSorpTM 384 well c lear plates 
MaxiSorpTM 96 well clear plates 
Ni trocel lulose membrane fil ter paper sandwich 
OASrrun pore size 
Penici l in-Streptomycin solution ( 1 00 ml sol ut ion! 
1 0,000 units penic i l l in ,  1 0 ,000 units 
streptomycin) 
Phosphate buffered saline ( PBS) tablets 
Polyethylene glycol 4000 
Sodium Azide ( aN) 
Sodium dodecylsulphate (SDS) 
SP2/0-Ag1 4  Cel l  Line murine 



























Cul ture Col lection 
Con t i n u ed Ta b l e  2 .2 :  Summary of chemicals/equipments 
MaterialslEqUJpment 
uperSignal We t Fernto Chemi luminescent 
ub trate 
uperSignal West Pico Chemi l uminescent 
ubstrate 
TEMED 
Ti_ sue culture overs l ips 25nun (plastic) 
Tis ue Culture Fla k 25CM 
Tissue Culture Fla k 75 M 
Tissue Culture Flask 75 M X75CM 
Ti sue Cul ture Pl ates 24 Well 
Ti ue Culture Pl ates 96 Well 
r i  sue Culture Plate 96 Well 
TMB substrate 
p-mercaproethanol 
Tab l e  2 . 3 :  Summary of antibodies used 
Commercial antibodies 
















Anti-a- synuclein (2 1 1 ) mouse monoclonal antibody 










Ant i-�-syn (8)  mouse monoclonal antibody 
Anti-y- synuclein (C-20) goat polyclonal antibody 
Anti-alpha Synuclein (Phospho S 1 29) mAb 
(EP J S36Y) 
Anti-Tau (SE2) mouse monoclonal antibody 
Anti-human Amyloid beta (N) (82E l )  mouse 
monoclonal antibody 
Antl- Amyl in ( R l  0/99) mouse monoclonal antibody 
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Abcam 




2.3 Solutions and buffers 
A .  P h osphate Buffered S a l i n e  ( PBS), p H  7.4 
One PBS tablet was dissolved in 200 ml steri le disti l l ed water (dH20) and 
then fi ltered through a 0.2 flm fil ter and stored at 4°C. 
B. P h osph ate b u ffered sal i n e  with 0.05% Tween-20 ( PBST) 
PB with 0.05% Tween-20. 
C .  200 mM N a H C03, p H =  9.6 
4.2 g of aHC03 was d issolved in  about 230 ml of steri le water, and then pH 
was adjusted to 9.6 at RT with 3 M  NaOH.  The final volume was made up to 250 
ml  with steri le  water and then the buffer was fil tered through a 0.2 flm fi lter and 
stored at 4°C. 
D. R l P A  b u ffer (50mM T ris, 1 50 m M  NaCl,  0.5% sod i u m  deoxycholate, 1 % 
N P-40, 0. 1 %SDS) 
5 ml  of 1 M  Tr is  pH= 8 was added to 90ml of steri le dH20, and 0.88 g of 
aCI  was dissolved fol lowed by 0 .5  g of sodium deoxycholate. Then 1 ml of NP-
40 was added and 0. 1 g of  SDS were added and the final volume was made up to 
1 00 m! .  The buffer was fi ltered through a 0.2 flITI fi l ter and stored at 4°C. 
E. A rt ificia l  CS F (ACS F)" 
S o l u t ion A The fol lowing (5 . 1 9g aCl ,  0. 1 34g KCl ,  O. I 23g CaCI2. H20, 
0.0975g MgCI2 .6H20) w�re dissolved in 300 m l  of steri le  dH20 and the buffer 
was fi ltered through 0.2 flm and then stored at 4°C.  
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o l u ti o n  B 
The fol lowing (0. 1 28g a2H P04.7H20, 0 .0 1 6g NaH2P04.H 20) were 
d i  solved in 300 m l  of sterile  dH20, and the buffer was fi l tered through 0.2 !-lm 
and then stored at 4°C. 
Soluti n A and olution B were m ixed in equal proportions before use. 
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CHA PT E R  T H R E E :  D evel o p m e n t  a n d  C h a racte r izat ion of  
C o n fo r m a t i o n-Spec i fic  M o n o c l o n a l  A nt ibod ies fo r (l­
Sy n u c l e i n  Aggregates 
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3.1 Introduction 
a-Syn is central to the pathogenesis of PD and other neurodegenerative 
diseases. Developing monoclonal antibodies capable of targeting pathological 
forms of a-syn is of great importance. Increasing evidence suggests that a-syn 
o l igomers (o-a-syn) p lay a crucial role in the pathogenesis of PD (Dimant et aI . ,  
20 1 3 ; el -Agnaf & I rvine, 2002; El-Agnaf, Walsh, et  at . ,  2003 ; H. 1 .  Lee, 
Kho haghideh, Patel & Lee, 2004; Paleologou, et aI . ,  2009' Tokuda, et a\ . ,  20 I 0; 
Winner, et at . ,  20 1 1 ) ,  and therefore, antibodies that can selective ly  target the 
pathogenic species of a-syn may open doors for developing effective diagnostic 
and therapeutic strategies for synucleinopathies. Toward this end, we developed 
h igh l y  selecti e mouse monoclonal antibodies ( roAbs) that target the pathological 
pecies of a- yn. In this chapter, we present the methodology used to develop and 
characterize six novel conformation-specific mouse mAbs that spec ifical l y  
recognIze a-syn pathological forms. Two more mouse mAbs and one sheep 
polyclonal antibody targeted against a-syn were also generated and characterized. 
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3.2 Methods 
3 .2 . 1  Prepa rat ion of i mm u n ogen 
The inununogen employed for the development of the monoclonal antibodies 
was composed of aggregates of a- yn. a-Syn fibri ls were generated using a 
solution of  rec mbinant human a-syn at a concentrat ion of 50 �M. a-Syn 
aggregation was induced by continuous mixing in a Themlomixer (Thermomixer 
compact, eppendorf) (800 rpm) at 3 7° for 7 days and was monitored using 
th ioflavin- (Th-S) binding assay. After the fibri l lation was complete, the 
aggregates were aliquoted into smal l aliquots and stored at -80°C unti l required. 
3 . 2 . 2  I m m u n ization 
BALB/C female mice (6-8 weeks old) were immunized subcutaneously with 
a-s) n aggregates. Each mouse received an in i tial immunization of 50 �lg of a-syn 
aggregates in a solution that was mixed with Freund's  Complete Adj uvant ( 1 :  1 
v/v) .  Fol lowing a 3-week interval, the in itial immunization was followed by a 
boo ter immun ization of  25  �g of antigen mixed with Freund 's Incomplete 
Adj uvant ( I :  1 v/v). On the 1 0th day after the booster immunization, blood was 
col lected from the tai l vein and antiserum was separated. Using the antisera, the 
antibody re ponse was evaluated with an indirect ELISA. The mice selected for 
fusion were subjected to a fi nal immunization of 1 50 �g of the immunogen at 3 
days prior to fusion. 
3.2.3 I ndirect ELI S A  for the assess ment  of the i m m u ne response of the hosts 
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A 96-wel l  clear Maxi orb plate (Nunc) was coated with 1 00 �l per wel l  (70 
ng/wel l )  of a-syn aggregates in PBS and incubated overnight at 4°C. The 
fol lowing day the p late was washed three times with PBST (PBS containing 
0.05% Tween-20) and blocked with blocking buffer (PBST containing 2 .25% 
gelatin) for 1 h at room temperature (RT). The plate was then washed three t imes 
with PB T and I 00 �I of serial ly d i luted antiserum (the ini t ia l d i lution was 1 :  1 00, 
fol lowed by J 0 di l utions) from the mice was added to the wel ls  in dupl icate. The 
plate \Va then incubated at RT for 1 h. ext, the plate was washed with P BST, 
goat anti-mou e I gG-HRP ( 1 :20 K, Jackson) was added ( l 00 �I/v el l )  and the 
plate \Va incubated for 1 h at RT. The plate was then washed three times with 
PB T and incubated \ i th 1 00 �l of TMB substrate (KP L) until the color 
de eloped. The reaction was stopped by adding 0.6 N H2S04 ( I  00 �I/wel l ) .  The 
ab orbance was measured at 450 nm using a VictorX3 microtiter plate reader. The 
ho ts that exhibited a good i mmune response were selected for fusion. 
3 .2.4 Generation of  m o u se a n t i -a-syn hybridomas 
Splenocytes from mice exhibiting high titers were fused with mouse myeloma 
cel l s  (Sp20-Ag 1 4 ; American Type Culture Col l ection) at a 5: 1 rat io using 50% 
polyethylene glycol ( M W  4000; Merck). After fusion, the cel ls were seeded and 
cul tured in 96-well  plates at a density of 2 .4  1 05 cel ls/well  in  lMDM (Gibco) 
selection media containing 2 m M  Glutamax (Gibco), 1 00 U/ml penici l l in  and 1 00 
�lg/m l streptomyc in  (S igma), 50 �g/m l gentamyc in (S igma), 50 �M �­
mercaptoethanol (Sigma) and 20% fetal bovine serum (Hyclone) supplemented 
with HAT ( l x  Sigma) and 6 x 1 03 macrophages (6 x 1 03 cel ls/wel l ;  freshly 
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i so lated from 5-6-week-old BALB/c mice). Hybridomas positive for a-syn fibrils 
were identi fied by analyzing their supernatants with ELISA (see the fol l owing 
section) . 
3.2 .5  crce n i ng for posit ive clones u ing  E L I S A  
To identify po i tive hybridomas supernatants from the growing fused cell s  
were creened using E LISA.  A 96-wel l clear MaxiSorb plate (Nunc) was coated 
\\ ith 1 00 III of a-syn aggregates in PBS ( 1  Ilg/ml ) and incubated overnight at 4°C. 
The fol lowing day, the plate was washed three times with PBST and blocked with 
blocking buffer for 1 h at RT. The plate was then washed with PBST, and 1 00 III 
of culture upematant from the fused cel l s  was added to each wel l .  The plate was 
incubated at RT for 1 h and then washed three times with PBST prior to the 
addition of the econdary antibody. The plate was washed with PBST and then 
incubated with TMB substrate ( l 00 Ill/we l l ;  KPL) unti l  the color developed 
appropriately. The reaction was stopped by adding 0.6 N H2S04 ( l 00 Ill/wel l ) ,  and 
the ab orbance was measured at 450 nm using a Victor3 1 420 multi- label 
microtiter p late reader. The positive hybridomas were transferred into a 24-wel l 
p late and screened again to identify stable clones. 
3 . 2 . 6  Sandwich E L I SA for i sotyp i n g  of posit ive hybridomas 
A 96-wel l  c lear MaxiSorb plate (Nunc) was coated with 1 :  1 K anti-mouse 
heavy-chain antibodies ( Isotyping Kit, Sigma) in PBS and incubated overnight at 
4°C. The fol lowing day, the plate was washed 3 times with PBST and b locked 
with blocking buffer (400 Ill/wel l )  for I h at RT. The plate was then washed 3 
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t imes with PBST, cul ture supernatant from each clone was added to each wel l  ( 1 00 
, .. d/wel l ), and the plate was then incubated for 1 h at RT. Next, the plate was 
washed and then i ncubated with secondary antibody for 1 h at RT. The p late was 
\ ashed \i ith PB T and incubated with TMB ( l oa f..l l/wel l ;  KPL) unti l the color 
bad developed appropriately. The reaction was stopped by adding 0.6 N H2S04 
( I 00 �tllwel l ) ,  and the ab orbance was measured at 450 nm using a Victor3 1 420 
mult i - label microtiter plate reader. The I gG-positive c lones were transferred into a 
25  cm
2 
flask and then SUbjected to single-cel l cloning. 
3.2 .7  ingJe cell  c lon ing 
Cel ls were coI l  cted from the cultures of posi tive hybridoma clones and were 
counted and di luted in I M DM .  Approximately 1 00 cel ls were taken and added to 
20 m l  of IMDM (Gibco) supplemented with Glutamax (2  mM, Gibco), 1 00 V/mi 
penici l l in  and 1 00 f..lg/ml streptomycin ( Penstrep, igma), 50 f..lg/ml Gentamyc in 
( igma) .. 50 f..lM p-mercaptoethanol ( Sigma) , 20% fetal bovine serum (Hyclone) 
and macrophages (6000 cel ls/wel l )  that were fresh ly i so lated from young BALB/C 
mice .. The cel ls were mixed and plated (200 f..lllwel l )  in a 96-wel l ti ssue culture 
p late and incubated in 5% CO2 at 3 7°C. The hybridomas were al lowed to grow. 
The wells containing single cel l s  were marked, the cel ls were al lowed to grow to 
con fluency, and the culture supernatant was then col lected and screened u ing an 
indirect ELISA. The ELISA-positive cel ls were transferred into 24-wel l plates and 
creened again prior to transfer to 25 cm
2 flasks. The culture supernatant from the 
2 5  cm2 flasks was screened at least three times prior to the selection of  stable 
c lones. 
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3.2.8 M ass c u l t u re a n d  p u ri fication of m on oclonal  a n ti body 
The selected clones were cultured on a l arger scale (mass culture) . The c lones 
were cult ivated in CDM4rnAb (Hyclone) supplemented with 2 mM Glutamax 
(Gibco). 1 00 V/m l penic i l l i n, 1 00 f-lg/ml streptomycin (Penstrep, igma), 50 f-lg/ml 
Gentamycin ( igma) and 50 f-lM beta-mercaptoethanol (Sigma). Once the cel l s  
were confluent and the color of the media had turned yel low, the culture 
sup rnatants were col l ected and stored at -20°C unti l required for use. The 
monoclonal antibodies were purified from the culture supernatants using protein 
G-agarose affinity chromatography. Protein G-agarose columns were prepared and 
equi l ibrated using 20-bed volumes of 20 mM phosphate buffer, pH 7 .2 .  The 
culture supernatant (200 m l )  was centrifuged at 1 500 rpm for 1 0  min at 4°C. The 
supernatants were col lected and passed 5 -6 times through the columns at a flow 
rate of approximate ly 1 m llmin. The columns were then washed with I S-bed 
volumes of  20 m M  phosph ate buffer pH 7 .2  to remove unwanted proteins. The 
bound antibody was eluted using 50 mM glycine, pH 2 . 5  into 1 . 5 ml  centri fuge 
tubes containing 50 �tl of neutral izat ion buffer ( I  M Tris, pH 8 .0) .  The puri fied 
antibody was final l y  dialyzed against PBS.  The antibodies purified from different 
batches were pooled, and the concentration was determined using a BCA assay. 
These monoclonal antibodies were lyophi l ized prior to storage at -20oe in 1 00 f-lg 
al iquots until required for use. 
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3 . 2 . 9  Dot Blot 
Monomeric and aggregated forms of U-, p- and y-syn; tau; Abeta-42; Islet 
Amyloid Polypeptide ( I APP) ;  or ABri were used for exploring the spec ificity of 
our mAbs. Each protein was spotted (50 ng) onto a nitrocellu lose membrane and 
al lowed to dry at RT for I h. The membranes were then incubated for 1 h at RT 
with 5% skimmed mi lk in PB T with gentle agitation. The blocking solution was 
then remo ed, and the membrane were incubated for 2 h at RT with the primary 
antibodie . The membrane were then washed three times with PBST and 
incubated with secondary antibodies - goat anti-mouse H RP ( I  :20 K) or goat anti­
rabbit ( 1  :20 K) as appropriate - for 1 h at RT. The membranes were then washed 
three t imes with PBST and developed using SuperS ignal West Pico 
Chemil uminescent Substrate (Pierce). 
3 . 2 . 1 0  Western Blott ing 
Samples of human-, mouse- and rat-brain Iysates ( 1 5  )lg), a - ,  p- or y-syn (50 
ng) were mixed with loading buffer (250 m M  Tris-HCI, pH 6 .8 ,  30% glycerol, 
0 .02% bromophenol blue) and then separated on 1 5% SDS-PAGE gels. The 
separated proteins were transfelTed to 0.45 )lm n i trocel lulose membranes 
( Whatman Gmbh-Germany) at l OO V for 45 min.  The membranes were boiled for 
5 min in PBS and then blocked for I h with 5% non-fat mi lk  prepared in PBST 
prior to incubation with 1 0  ml of primary antibody (50 ng/ml) for 2 h at' RT. The 
membranes were then washed 4 times with PBST fol lowed by incubation with the 
S2 
secondary antibody. The membranes were then washed 4 t imes with PBST and , 
i mmunoreactive bands were v isual ized using the SuperSignal West P ico 
Chemi luminescent Substrate Kit ( Pierce) according to the manufacturer' s  
i nstructions. 
3 . 2 . 1 1 I m m u n o h i  tochemist ry 
I Ten-micron, formal in-fixed, paraffin-embedded sections were cut from the 
anterior cingulate cortex of PD cases and aged-neurological control cases. The 
sections were de-waxed in xylene (2 x 1 00% washes) and rehydrated through 
descending concentrations of ethanol (2 x 1 00%, 1 x 95%, 1 x 70%, 1 x dH20) 
fol lowed by fonnic acid (90%) antigen retrieval for three min. The sections were 
washed in  Tris buffer (PH 7 .2)  fol lowed by washing in 50% ethanol containing 
1 % H202 to b lock endogenous peroxidase activity. After washing in Tris buffer, 
e tions were blocked for 20 min in Tri s  buffer containing 1 0% normal horse 
serum. The sections were then incubated overnight at 4°C with the following 
antibodies:  Syn- l ( 1  : 200; BD), ant i-p-S 1 29-a-syn antibody ( EP 1 536Y; 1 : 500; 
Abeam), Syn- F l ( 1 : 1 0  K), Syn-F2 ( 1 : 5 K), Syn-O l ( 1 : 1 0  K), Syn-02 ( 1 : 5 K), 
Syn-03 ( 1 : 5 K) or Syn-04 ( 1 : 5 K). A fter three washes in Tris buffer, the sections 
were incubated with biotin-conj ugated horse anti-mouse ( 1 :200; Vector 
Laboratories) or goat anti-rabbit ( 1 : 200; Vector Laboratories) anti era, as 
appropriate, for 30 min at 3 7°C. Following three washes in Tris buffer, the 
sections were incubated in avidin-biotin complex ( 1 : 500; Vectastain El ite Kit;  
Vector Laboratories) for 30 min at room tempelature followed by DAB 
I Immunohistochemistry was conducted by our collaborator Prof. Gl enda Hall iday, Uni versity of New 
South Wale , Sydney, Austral ia .  
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i ncubation ( 1  x 1 0  mg DAB tablet in 1 5  ml Tris buffer) . The peroxidase reaction 
was i nit iated by adding 0 .0047% H202 to tile DAB solution. The development of 
a dark-brown reaction product was monitored by eye under a dissecting 
micr scope and stopped using two quick washes in  Tris buffer prior to a final 
wash in d H20. Th sections were counter-stained with 0.5% cresyl violet and 
dehydrated through ascending concentrations of ethanol ( 1  x 70%, J x 95% and 2 
x 1 00%) and c leared in xylene. The sect ions were cover-sl ipped using DPX 
water-free mounting media. 
Al l  ti uc was isual ized usmg a Zeiss Axioskop mIcroscope (Munchen­
Hal lbergmoos, German ), and 8 -bit RGB images of D AB-stained sections were 
captured u ing a Zeiss AxioCarn HRc camera and AxioVision 4 .7  software. For 
figure production, no adjustments were made to RGB images except for minor 
adj ustments to brightness and contrast with the levels command in Adobe 
Photo hop CS6 (San Jose, CA) to best represent the staining observed directly 
under the microscope. 
3 .2 . 1 2  S a ndwich E L I SA for test i n g  specific i ty tow a rds o-a-syn 
A 3 84-well ELISA m icroplate (Nunc Max iSorb NUNC) was coated 
overnight by incubating the tested mAbs (0. 1 )1g/ml) in 200 mM NaHC03, pH 9 .6 
( 50 )1 l/wel l) ,  at  4°C.  The plate was washed with PBST and incubated with 
block ing buffer ( l 00 )1l/wel l )  for 2 h at 37°C. After washing, 50 )11 of the sanlples 
for test ing was added to each well (a-syn monomer, ol igomer or proto fibri l 
so lutions), and the p late was then incubated at 3 7°C for another 2 . 5  h. FL- 1 40, 
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d i l uted in blocking buffer ( 1 / 1  K), was added after washing the plate 4 times with 
PBST which was then incubated at 37°e for 2 h .  The p late was washed and then 
incubated for 1 h at 3 7°e with 50 �Vwel l  of goat anti-rabbit IgG H RP (Jackson) 
di l uted to 1 :  1 5  K in b locking buffer. Bound H RP activity was assayed based on a 
chemi luminescent reaction using the enhanced chemi luminescent substrate 
uper ignal ELl A Femto (Pierce), after which chemi l um inescence in relative 
l ight unit was immediately measured using a Victor3 1 420 (Wal lac) microplate 
reader. 
3.3 Results 
3.3. 1 An tibody response i n  a-syn i m m u n ized m i ce 
To raise spec i fic monoclonal antibodies for a-syn pathologies recombinant (X­
syn aggregates were employed as immunogens. Fol lowing booster immunizations, 
the mice were b led to assess antibody responses, and a high response fol lowing the 
second booster immunization was obtained ( Fig. 3 . J . 1 A-F) .  The reason for this 
h igh response maybe that aggregated proteins are general ly  more immunogenic 
than their monomeric forms (Qian et a! . 20 1 2) .  Prior to using mice for fusion, pre­
fusion t iters (after 1 month of rest) were performed to assess whether the antibody 
response remained elevated. When the titer value was reduced to at least hal f of 
the peak value, the antibody-producing splenocytes of the mice were isolated and 
fused with mouse myeloma cel ls  to generate hybridomas that secrete antibodies. 
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Fig.  3 . 1 :  ntibody response from a-syn immunized mice 
Titer check for hosts immunized with a-syn aggregates (A-F). 
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3 .3.2 elect ion of po i tive h b ridom a clones 
To ident i fy the hybridomas that produce antibodies against a-syn aggregates 
the hybridoma supernatants obtained from the fusion of mice splenocytes with 
mou e m  eloma cell \ a assessed for binding to a-syn aggregates. For this 
purpo e an indirect ELl  A was perfonned using the supernatant from the 
hybridomas as the primary antibody. A total of 1 1 00 positive c lones were obtained 
from the in itial screening, but only 1 00 clones were selected for further 
charact rization. 
The isotypes of the antibodies selected for the EL ISA positive c lones were 
i dentified using an isotyp ing kit .  Out of the 1 00 clones identified, only 33  parental 
c lones were found to be of the I gG isotype, whereas the remaining clones were 
ei ther I gM or a mixture of IgG and I gM isotypes. The c lones secreting I gG 
antibodies \ ere selected, passaged multiple times to ident ify stable c lones and then 
subjected to single-cell c loning to achieve monoclonal ity. The single-cel l  clones 
obtained were transfened to 24-wel l plates, and their tabi l ity was assessed using 
E L I SA. The stable clone were then cultivated in 25 cm2 flasks for further 
characterization. 
The spec i ficity of the mAbs produced for a-syn aggregates was assessed using 
dot blots. Out of a total of 278 c lone , 45 clones were found to be stable. Out of 
these 45 c lones, only 6 stable c lones (Syn-F I ,  Syn-F2, Syn-O l ,  Syn-02, Syn-03 
and Syn-04 ) \\ ere speci fie to a-syn aggregates. Two c lones, 1 1 0 1 2  and 7 A l l ,  
which reacted to both monomeric and aggregated forms of a-syn, were also 
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selected for further characterization. Four c lones were found to be IgG l three 
c lones were IgG2a, and one clone was found to be of the IgG2b isotype (see Table 
3 . 1 ) . 1 1  D 1 2  and 7 1 1  detected monomeric, ol igomeric and fibri l lar forms of a-
yn with simi lar affinity (Fig. 3 .2) .  However, Syn-F l & 2 and Syn-O l -4 
peci fical ly detected a-syn aggregates but not a- yn monomers (Fig. 3 .3 ) .  Syn- l 
(anti -a-syn) mouse rnAb (BD biosciences) or 2 1 1 (Santa Cruz) were employed as 
p i t ive controls .  
Ta ble 3. 1 Generated CLones ' Isotypes 
Clone ID Isotype Clone ID Isotype 
yn-F l  IgG l Syn-03 IgG I 
yn-F2 IgG2a Syn-04 IgG I 
Syn-O l ] gG2b I l D 1 2  IgG2a 
Syn-02 I gG 1 7A l l IgG2a 
- � � "< 0 » r-- Vl 
a-syn monomers 
• • 
u-srn pro'ofibrils • 
• 
a-syn oligomers • • • 
Fig. 3.2 :  Spec i ficity of anti-a-syn antibodies towards a-syn. 
50 ng of recombinant ful l  l ength monomeric, ol igomeric 
aggregated a-syn were spotted into nitrocel lu lose membranes 
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Fig.  3 . 3 :  
Syn·F2 Syn-01 Syn-02 Syn-03 Syn-04 
pec i ficity of conformation-specific mAbs towards o.-syn 
aggr�gatc . 
50 ng of  recombinant ful l  length of o.-S) n mon mer (M)  and fibri l (F )  
\\ ere n tted into ni trocel lu lo e membranes and probed with the 
3 .3.3 Affi ni t)  of th generated m Ab 
To detem1 in� the affi nity of yn-F l ,  yn-F2, and yn-O 1 -4 for CL-syn 
aggregate:, an inhibiti 11 E L I  was performed. The inh ibition ELISA i an 
indirect E ll used to a ess whether the pre-incubation of the antibodies 
generated \\ ith CL- yn fibri l or monomer inhibits the abi l ity of these antibodie to 
detect coated 0.- yn fibri l . Al l  six antibodie were shown to be highly selective for 
a- ')11 fibri l  compared wi th monomers, a hown in Fig. 3 .4 and Table 3 .2 .  Syn- I ,  
empl o  ed a - a controL exhibited an almo t equal reactiv ity to\\ ard both a-syn 
fi b ri l  and monomer . 
mAb 
IC50 ( 11M) Fold affinity 
for a- yn for a-syn towards CL- yn 
I D  
fibri l s  monomer fibri l 
yn-F I 0 .000 1 2  2 .083 1 6558  
yn-F2 0 .00 1 1 .., .707 3 1 4 1  
yn-O l 0 .00037 4.793 1 2737 
Syn-02 0.000 1 2  3 .283 273 1 2  
yn-03 0.00047 5 . 329 1 1 1 29 
yn-04 0.00052 3 .605 6932 
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Fig. 3 .4 :  Affinity the generated mAb . 
.. .. 
L oC C O DUDLrabOaO(CL-S,pa. 
I nhibition EL I  A demonstrating the binding preferenc s of our mAbs. 
The commercial ly  avai lable antibody Syn- l is also i nc luded. Our mAb 
d isplaJed a marked selectivity for a-syn aggregates ( e )  versus monomer 
( � ) . yn- I had an equal preference for both fom1s. 
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3.3.4 O u r  c o n formation- pecifi c  mAbs do n ot cross-react with a myloid fibr i ls  
formed by other n uclei n s  o r  u n related amyloid protei n s  
To evaluate the  spec ificity of  our mAbs, monomers and fibri l s  o f  a-syn, tau 
protein, p-amy loid ( P), I let Amyloid Polypeptide ( lAPP) and ABri and fibri l lar 
fonns of  P- or y-syn \ ere blotted onto a nitrocel lulose membrane and probed with 
our antibod ies \ i th appropriate positive control antibodies. Surprisingly, the 
se lect d antibod ie \ ere shown to be exclusively specific for a-syn fibri ls  because 
the) did not recogn ize amyloid fibri ls  formed by other proteins, including p- or y-
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Fig. 3.5:  Speci ficity of generated mAbs to a-syn aggregates. 
50 ng o f  both monomers ( M )  and fibri ls ( F )  of a-syn, tau l APP or 
ABri were spotted onto n itrocel lu lose membranes. The membranes 
were probed with the indicated antibodies. 
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Fig. 3 .6 :  Spec ific i ty of our cmAbs to synuclien fibri l s. 
50 ng or  both monomeric (M)  or fibri ls ( F) of recombinant 
U-, �- and 'Y- were spotted onto n i trocel lu lose membranes. 
Then the membranes were probed with the ind icated 
antibodies. 
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The six selected conformation-speci fic mAbs were also assessed for their 
cross reactivity with amyloid fibri ls  formed by di fferent fragments of a-syn. Fibril s  
and monomers from ful l - length a-syn ( 1 - 1 40) and a-syn fragments i .e . ,  a-syn (1-
1 22),  AC (6 1 -95) and AC (6 1 -78) were tested. one of  the six conformation-
spec ific antibod ies reacted with fibri ls formed from any of the a-syn fragments; 
th Y recognized onl y  the fibri l s  fom1ed by the ful l - length a-syn ( 1 - 1 40), 
uggesting that a part of the epi tope for these mAbs is within the C-terminal region 
(Fig .  .7) .  
F M F M F M 
o. syn 1 140 • • • 
o. syn 1 122 
NAC (61 95) 
NAC (61 78) 
Syn F1 Syn F2 
F M F M 
a·syn 1 ·140 • • • • 











Fig. 3 . 7 :  Spec i fic i ty of our mAbs towards the fibri l formed by 
ful l - length a- yn protein. 
50 ng of  both monomeric ( M) and fibri l s  (F) of the ful l - length a­
syn or a-syn fragments ( 1 - 1 22, 6 1 -95 and 6 1 -78) were spotted onto 
n i trocel lu lose membranes, then probed with the indicated 
antibodies. 
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3 .3 . 5  l l D 1 2  a n d  7 A l l m b s  do not cross-react  wit h  other syn uclei ns 
To explore the speci fic ity of I l D 1 2  and 7A l l for u-syn, human u-, �- and y-
yn were used [or We tern blotting. Western blotting revealed that both I l D 1 2  and 
7 A l l were spec ific  for u-syn, and no cross-reacti ity against �- or y-syn (Fig. 3 .8)  
w as observed. 
� � � (f, en en I I 13 en ?--
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F ig. 3.8:  Spec i ficity of ant i -u-syn antibod ies towards synuc1ein 
proteins. 50 ng of recombinanl U-, �- and y-syn \ ere loaded on SD 
aels and transferred to ni trocel lu lose membranes for western b lotting. b 
The membranes were then probed with indicated antibodies. 
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3 .3.6  Specificity of l l D 1 2  a n d  7 A l l to Q - yn 
To investigate the specificity of l I D 1 2  and 7 A l l mAbs towards different a-
yn species, including human, mouse and rat brain 1ysates were tested. Western 
blot analysi for 7A l l revealed a band about 1 4-kDa in al l brain lysates 
repre enting ful l- length a-syn whi le  the same band was detected only in the human 
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Fig. 3.9 : Speci ficity of anti-a-syn ant ibodies towards a-syn homologs. 
1 5  flg of human, mouse and rat brain Iysates were loaded on SDS gels and 
transferred to ni trocel lu lose membranes for western blotting. The 
membranes were probed with indicated antibodies. 
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3 .3.7  C ro s-reactivity o f  1 1 D 1 2  and 7 A l l mAbs wit h  modified forms of u- yn 
To i l lustrate the binding specificity of these two mAbs to o-a-syn and post-
translational mod i fied forms of a-syn, monomeric,  o-a-syn, p-S 1 29-a-syn and 
ni trated a-syn were potted onto ni trocel lulose membranes. Dot blot analyses 
revealed that 1 J D 1 2 recogn ized al l three forms of a-syn whereas 7A l l  recogruzed 
only o-a- n and n i trated a- yn with no cro s-reactiv i ty to pS 1 29-a-syn ( Fig. 
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F i g. 3 . 1 0 :  Cross-reacti v ity of anti-a-syn ant ibodies with di fferent 
spec ies of a-syn. 50 ng of human monomeric, o l igomeric, n i trated and 
p-Ser l 29 were spotted onto nitrocel lu lose membranes for dot blotting. 
The membranes were then probed with the indicated antibodies. 
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3.3.8 I mmuno taining of a- y n  pathology i n  human brain with our crnAb 
I n  PO case , yn- l  labeled LB and numerous L s predomi nantly in deeper 
cort ical layer of the antenor cingulate cortex, whereas anti -p-S I 29a-syn ( E P I 536Y) 
labeled a greater propol1 10n of  L8s;  however, LNs were parse. LB labeled with 
' P 1 536Y \'" ere larger in  size than tho e labeled w ith Syn - l (Fig. 3 . I I A, 8) .  Very 
fai nt synapt lc ynuclein- immunoreacl ivity \: as observed with EP 1 536Y. Syn-F l ,  
yn-F2, and yn-O 1 -4 labeled a s imi lar number of LB of simi lar s ize and L s as 
E P 1 536Y ( Fig. 3 . I I C-H) .  Only very faintly immunoreactive synapt ic syn was 
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yn-03 )'n-04 
Fig. 3 . 1 1 Immunostaining of a-syn on human P D  brain 
t i  sue. 
I mages howing LB immunoreactive for Syn - l ( ), 
EP I - 36Y (8)  and our ix mAbs (C-H) in the anterior 
cingu late cortex from a ca e w ith PD. Sections are 
counterstained w ith Cresyl violet (blue). Scale bar 
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3 .3.9 Develo p m e n t  of peei fi e  a n dwich E L I S A  for (l-syn oligomers 
The EL ISA is based on a sandwich system in which the antibody for 
c apturing is  ne of our novel conformation-specific mAbs and the antibody for 
detection is FL- 1 40, a rabbit polyclonal anti-a-synuclein antibody (Santa Cruz). 
Serial d i lutions of  a-syn monomers, o l igomers and protofibri ls  were used to 
evaluat this ELI  A. o-a-Syn was prcpared by mixing recombinant human a-syn 
with Gn Rb 1 to induce the [onnation of soluble SDS-stable ol igomers that were 
charactelized by electron microscopy, We tem b lotting and gel fi l tration (Ardah et 
aI. , manu c ripl submitted for publ ication). For a-syn protofibri l preparation, we 
used a protocol s imi lar to that described by the Lee V.M.  research group (Norris 
et al . 2005).  a-Syn ol igomers and protofibri l s  were detected specifical ly by our 
E L I  A, whereas the ELISA using S yn- l for capture showed equal detection for al l  
three fomls of a- yn (Fig. 3 . 1 2) .  
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Fig. 3 . 1 2 :  Characterizat ion of our mAbs spec ificity and robustness in 
andwich-EL ISA system ,  Hi stograms shown are representative of 3 
independent experi ments using serial di lutions (500)..lM- O,5)..lM)  of  
recombi nant Q- yn monomers, o l igomers and protofibri ls, Measurements 
were taken in dupl icate, and the results show the mean ± standard 
deviation for each point S ignal is  di played in relative l ight unit ( RLU) , 
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3 .3. 1 0  Syn- 1 40 C h a racteriza t i o n  
S yn- 1 40 i s  a heep polyclonal antibody raised against ful l-length human u-
syn. Western b lotting revealed that Syn- 1 40 specifical l y  detects u-syn of mouse 
rat and h uman as wel l as p-S 1 29- u- yn and nitrated u-syn. 
c c � >-. >-. en en � I I d C!l ?-
yn- l 40 -
anti-f3-syn (8)  
--
Fig. 3 . 1 3 : Spec i fic i ty of Syn- 1 40 towards synucle in proteins. 
50 ng of recombi nant U-, �- and y-syn were loaded on SDS gel 
and transferred to n itrocel lu lose membranes for western blott i ng. 
The membrane were then probed with indicated antibodi es. 
c c >-. >-. en en � C I tl >-. c C en <1) '" >-. � en E en :J 
� � 0 :J '" 2 ::r: .... c:r:: 
Syn- 1 40 .. � �  
Syn- l - �- -
Fig. 3. 1 4 :  Speci ficity of Syn- l 40 towards u-syn homologs. 
1 5  �g of human, mOll e and rat brain lysates were loaded on SDS 
gels and transferred to n itrocel l u lose membranes for western 
blotting. The membranes were probed with indicated antibodies. 
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3. 4 Di cu LOn 
a-Syn is the major component of LBs one of the defIning pathological 
hal lmarks in the brain of  patients with PD and DLB. Although the accumulation 
of  a- yn i central to the development of synucleinopathies, the precise mechanism 
remain uncerta in .  The aggregat ion of a-syn takes p lace in a multi -step, nucleated 
polymerizat ion pro ess in which a conformational shi ft of the monomelic structure 
re ults in partial l y  folded intermediate 'ol igomers' that grow in size and eventual ly 
accumulate a insoluble an1yloid fibri ls in LBs. Of the di fferent spec ies of  a-syn ,  
intennediate o l igomers/protofibri ls  are thought to  be  the major neurotoxic species. 
Therefore, de eloping therapeuti and diagnostic strategies that target these 
speci e  is of paramount importance. Several hypotheses have been developed 
regarding the me han ism o f  the neuropathogen ic ity of a-syn ol igom rs. Some 
groups have reported that a-syn ol igomers exhibit neurotoxic effects via the 
d isruption of cel lu lar membranes ( Danzer et a l . ,  2007; Winner, et al . ,  20 1 1 )  or by 
neuroinflammatory mechanisms ( Wi lms et al . ,  2009). Recently, Masliah and 
col leagues reported that o-a-syn exacerbates synaptic degeneration by interfering 
with synaptic esic le , leading to neuronal cel l  death ( Rockenstein et al . ,  20 1 4) .  
HO\ ever, the exact neuropathological mechan ism o f  a-syn ol igomers remains to 
be ful l y  e lucidated. 
I n  2003 ,  Kayed et al .  reported the development of A l l ,  a polyclonal antibody 
rai sed against A� 1 -40. In vi tro studies showed that A l l did not discriminate 
between ol igom ric species from different amyloid proteins, including a-syn 
( Kayed et al . ,  20 1 0). Another polyc lonal antibody described by EI-Agnaf et al . ,  
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Fi la- I ,  \ hich spec i fical ly recogn izes u-syn aggregates was used to detect o-u-syn 
in l ysates from po t-mortem DLB brains using indirect ELISA (Paleologou, et al .  
2009). Moreover, a human single-chain antibody fragment that b inds specificall y  
t o  o-u- y n ha also been developed and was reported to inh ib i t  u-syn aggregation 
and o l igomer-induccd toxic i ty (Emadi Barkhordarian, Wang, Schulz & Sierks, 
2007).  More recent ly, lng Isson and col leagues reported the development of two 
mou e m bs \\ ith high select iv i ty toward large ol igomers of  u-syn only 
( Fagerqvi t et a1 . .  20 1 3 ) .  
We used preparat ions of u-syn aggregates to  immunize female BALB/C mice, 
thereby PI' due ing mi\bs with high select i i ty toward u-syn o l i gomers/[ibri ls. 
Furthem10re, two mou e monoclonal antibodies equal l y  reactive to d i fferent 
species of  u- yn were also generated. A l l  of our rnAbs were thoroughl y  
characterized using mUlt iple methods, i nc luding immunoblotting, inhibi tion 
E L I SA, sandwich ELISA and immunohistochemistry. Next we employed our 
rnAbs to develop speci fic and sensitive E L I SA assays for the rapid and accurate 
quant ification of u-syn ol igomeric species. 
A l though several hybridomas secret ing mAbs spec i fie for u-syn 
o l igomers/fibri l s  were isolated only the clones that generated I gG isotype 
antibodies were selected. Considering the multivalent architecture of IgM 
antibodies, their potential therapeutic use is  compromised. In contrast, the simple 
d ivalent structure of I gG antibodies is  more suitable for future development as 
diagnostic or therapeutic tools. 
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I n  contrast with previously reported oligomer-specific antibodies our novel 
mAb do not cross-react with aggregated forms of other amyloid proteins, such as 
tau A�, am l in or I PP,  and interestingly they do not even recogn ize aggregates 
f, rmed by other s nuclein proteins such as �- and y-syn. 
Prior to characterization a l l  mAbs were purified using protein G agarose 
beads. Using immunoblotting in which the proteins were blotted onto 
n itrocel l ulose membranes, our conformation-specific antibodies (Syn-F l -2 and 
yn-O 1 -4) \\ ere h \. n to be highly select ive for a.-syn aggregates, whereas 1 1  D 1 2  
and 7 A l l \ver ho\ n to be specific for a.-syn.  
Consistent w i th our dot b lot  resu lts, inhibi tion ELISA analyses, in which a.-
yn monomers and sol uble aggregates were i n  solution, showed that our 
conformation-speci fic mAbs exhibited much higher affin ity for a.-syn soluble 
aggregates than for monomers. Our mAbs showed very strong afflnity for o-a.-syn 
compared with ther reported anti-o-cx-syn (Fagerqvist et aI . ,  20 1 3 ) .  The affinity 
was est imated as the molar concentration of free antibody required to achieve 50% 
of  the maximal binding calculated using binding curves. 
The mo t i mportant question was whether our novels mAbs could detect 
nat ive patho logical spec ies of cx-syn in LBs. I mmunohistochemistry was performed 
using our mAb on post-mortem brain tissue from patients with PD. Interestingl y, 
our mAbs c learly stained L Bs and both punctate and neuritic structures only. I n  a 
compaJison of the staining patterns between our novel mAbs and commercial 
mAbs (Syn- l and anti-phosphorylated Ser l 29 a.-syn), our mAbs showed a lack of 
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cro s-reactivity with synaptic u-syn, confirming thei r  specifici ty toward u-syn 
pathology. 
Add it ional ly, t further investigate the spec i ficity of our mAbs toward u-syn 
aggregates, our conformation-spec ific mAbs were used as capturing antibodies in 
sandwich ELI  As. ignals were detectable on ly from soluble a-syn aggregates 
confi nning our aforementioned results. 
I nter ti ngly, our research group has recentl y  shown that yn-0 1 A  recognizes 
both o luble and mature fibri ls, whereas Syn-F l and Syn-F2 recognize a-syn 
amyloid fibri l prefer ntial l y  compared with ol igomers (Vaikath et al. ,  manuscript 
submitted for publ ication).  
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C H A PT E R  FO U R :  D eveloping N ovel S a n d w i c h- E L I SA s  fo r 
M ea s u r i n g  a-Sy n u cle in  Species i n  Biological  F l u id s  
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4. 1 Introduction 
PO is the most common movement disorder; however, its diagnosis is primarily  
based on motor-related c l inical criteria. PO is characterized by a l arge t ime-gap 
between the begirul ing of the neurodegenerative processes and the onset of c linical 
neurological manifestat ions (Jankovic 2008). The natural history of the disease 
includes an initial a ymptomatic stage fol lowed by a I ng pre-motor phase; final l y, 
when the c lassical motor symptoms appear, the majority of nigra! dopaminergic 
neuron have already degenerated (Tolosa Gaig, Santamaria, & Compta, 2009). 
Therefore there is an urgent need for the development of biomarkers for PO 
diagnosis and prognosis .  Toward this aim, recent intensive investigations have 
attempted to identify biomarker(s) to enable the early diagnosis of PO, preferably 
during the pre-motor phase. Molecular changes in the brain are ref1ected in CSF 
composition, and this makes CSF an ideal source of rel iable biomarkers (Anoop 
S ingh, Jacob, & Maj i , 20 1 0) .  
a-Syn ha been consistently detected i n  biological f1uids such as human b lood 
p ia  rna and CSF ( Borghi, et aI . ,  2000; E I -Agnaf, Salem, et aI . ,  2003;  Moll enhauer, 
et a I . ,  2008) .  Recently, several studies have explored the potent ial use of CSF t-a­
yn as a putative biomarker for PD.  A c lear trend of lower CSF total a-syn (t-a­
yn) l evel in PO and other synucleinopathie ha been consistent ly reported, 
al though a l arge overlap between PO and control groups has been noted (Aerts, et 
a1 . ,  20 1 2 ; Hong et ai . ,  20 1 0; Mol lenhauer, et ai . ,  201 1 ;  oguchi-Shinohara, et aL 
2009; Pametti, et a i . ,  20 1 1 ;  Pametti, Farotti, et ai . ,  20 1 4; Spies, Mel is, Sjogren, 
R ikkert, & Verbeek 2009 ; Tateno, et a1 . ,  20 1 2 ; Tokuda, et aI . ,  20 1 0; Tokuda, et 
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aI . ,  2006). However, al l of  these studies noted that t-o.-syn levels alone could not 
d iscrim inate patients with synucleinopafuies [rom normal individuals or those with 
oth r neurodegenerative di eases. 
In contrast, combin ing the measurements of di fferent species of o.-syn may 
improve the d iscrimination between PD and other neurodegenerative diseases 
( Pametti ,  Farotti, et al . ,  20 1 4; Tokuda, et al . ,  20 1 0; Wang, et a l . ,  20 1 2) .  o luble 0.-
yn l igomcrs (0-0.- yn) have been increasingly l inked to synaptic and neuronal 
d generation ( Rockenstein, et aI . ,  20 1 4) .  It has been shown that soluble o-o.-syn is 
e levated in brain homogenates from PD and DLB cases compared with controls 
( Paleologou et aI . ,  2009' Sharon et aI . ,  2003 ).  The exact mechan ism by which 0.-
yn o l igomers cause neuronal ce l l  death is not ful ly  elucidated. Masliah and co­
workers reported in a recent study that o-o.-syn exacerbates synaptic and neuronal 
degeneration in vivo ( Rockenstein, et a l . ,  20 1 4) .  I nterestingly, several independent 
studies showed that o-a-syn l evels were sign ifi cantly higher in PD patients 
compared with other neurological di orders (Park, et aI . ,  20 1 1 ;  Parnetti, 
Chiasserini ,  et aI., 20 1 4; Sierks, et aI . ,  20 1 1 ). CSF o-a-syn Levels and o-a-synJt-a­
syn ratios were found to be substantial ly higher in patients with PD, inc luding 
those with mi ld  and early-stage disease, compared with individuals with other 
neurological disorders or those who underwent lumbar puncture for diagnostic 
purposes (Tokuda, et a I . ,  20 1 0). CSF o-a-syn shows a sensit ivity of 75 .0% and a 
spec ificity of  87 .5% for PD, and the CSF o-a-synJt-a-syn ratio shows a sensitivity 
of 89 .3% and a speci fic i ty of 90.6%. The�e findings have been confirmed in two 
independent reports (Park, et aI . ,  20 1 1 ; Sierks, et a l . ,  20 1 1 ) . 
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Wang et al. measured p-S 1 29-u-syn and t-u-syn levels i n  fresh CSF samples 
[rom a l arge cohort (-600 samples) of patients with varying types of parkinsonism, 
i nc luding P O, M S A  and PSP and healthy individuals. CSF p-S 1 29-u-syn levels 
showed a posi tive correlation with PD severity, and the combination of CSF t-u-
yn and p-S 1 29-u-syn improved the discrimination between PD and other forms of  
parkinsonism (Wang, e t  aI . ,  20 1 2) .  Taken together, these reports strongly suggest 
that o-a.-syn and p-S 1 29-a.-syn are potential candidates as CSF biomarkers. 
In thi tudy, we developed specific and sensi tive ELISA assays using our novel 
c n formation-speci fi c  mAbs for measuring CSF o-u-syn. Moreover, we also 
developed a new EL ISA for measuring CSF t-u-syn and a third ELISA for 
measuring CSF p-S 1 29-a-syn in .  I n  addition, the c lassical AD CSF biomarkers 
total-tau ( t-tau), phosphorylated-tau (p-tau) and Amyloid-beta 42 (A�-42) were 
inc luded in our study. 
4. 2 Methods 
4 . 2 . 1 Devel o p m en t o f  E L I SA for meas u ri n g  total  u-syn i n  h u m a n  CSF 
A 3 84-wel l  EL ISA microplate ( unc MaxiSorb, NUNC) was coated in an 
overnight incubation at 4°C with 0. 1 flglml sheep polyclonal anti-u-syn antibody 
(Syn- 1 40) in 200 mM aHC03, p H  9 .6  (50 flllwel l ) .  The plate was washed with 
PBST and incubated � ith blocking buffer ( 1 00 flllwel l )  for 2 h at 37°C. After 
washing, 50 fl l o f  the CSF samples ( thawed on ice; Tween-20 was added to a final 
concentration of 0.05%) was added to each wel l ,  and the p late was then incubated 
at 3 7°C for an additional 2 . 5  h. 1 1 0 1 2  d i luted in b locking buffer (0.2 flglml )  was 
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added, and the plate was incubated at 37°C for 2 h .  The p late was washed and then 
incubated for 1 h at 3 7°C with donkey anti-mouse IgG H RP (Jackson; 50 Ill/wel l )  
d i luted in  blocking buffer ( 1  :20 K). After washing, the plate was incubated with 50 
Ill/wel l o f  SuperSignal ELISA Femto Enhanced Chemi luminescent Substrate 
(P ierce) .  The chemiluminescence, in relative l ight units, was measured 
i nunediately u ing a Victor3 1 420 (Wal lac) microplate reader. The samples were 
creened i n  a b l inded fashion and tested randomly. The case and control samples 
were run on a single plate to avoid plate-lo-plate variations, and the results were 
confi rn1ed u ing at least two independent experiments. A series of internal controls 
were also run to check for run-to-run variations. 
4 . 2 . 2  Deve l o p m e n t  o f  E L I S A  for measu ri n g  phospho rylated S 1 29 a-syn i n  
h u m a n  C S F. 
A 3 84-wel l  ELISA microplate (Nunc MaxiSorb, Nunc) was coated for 
overnight i ncubation at 4°C with Syn- 1 40 (0 .5 Ilg/ml )  in 200 mM NaHC03, pH 
9.6 (50 Ill/we l l ) .  The plate was washed with PBST and incubated with blocking 
buffer ( 1 00 Il l/wel l )  for 2 h at 3 7°C. After washing, 50 II I of  the CSF samples 
(thawed on ice; Tween-20 was added to a final concentration of  0 .05%) was added 
to each wel l and the plate was then incubated at 37°C for another 2 .5  h. Rabbit 
monoclonal anti-p-S 1 29-a-syn antibody (EP 1 536Y; Abcam) di l uted in b locking 
buffer ( 1 :2 K) wa added, and the plate was incubated at 3 7°C for 2 h. The plate 
was washed and then incubated for 1 h at 37°C with goat anti-rabbit IgG HRP 
(Jackson; 50 Il l/wel l )  d i luted in b locking buffer ( 1 : 1 0  K) .  After washing, the plate 
was incubated with 50 Il l/wel l of SuperS ignai ELISA Femto Enhanced 
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Chemi lurninescent Substrate ( Pierce) . The chem i luminescence, in relative l ight 
units was measured imm ediate ly using a Victor3 1 420 (Wal lac) microplate reader. 
The samples were screened in a bl inded fashion and tested randomly. The case and 
control samples were run on a single plate to avoid plate-to-plate variations, and 
the re ul ts \,: ere con fi rmed u ing at lea t two independent experiments. A series of 
internal control werc also run to check [or run-to-run variations. 
4 . 2 .3 Devel opment  of E L I SA for meas u ri n g  ol igomeric a-syn i n  h u m a n  CSF 
A 3 84-wel l  E LI SA microplate (Nunc MaxiSorb, unc) was coated by 
overnight i ncubation at 4°C with Syn-02 (0 .2  )lg/ml )  in 200 mM NaHC03, pH 9 .6 
( 50 )l llwe l l ) .  The plate was washed with PBST and incubated with blocking buffer 
( l 00 )lllwel l) for 2 h at 3 7°C. After washing with PBST, 50 )l l of the CSF amples 
(thawed on ice; Tween-20 was added to a final concentration of 0.05%) was added 
to each wel l ,  and the p late wa then incubated at 3 7°C for another 2 . 5  h. FL- 1 40, 
d i luted i n  b locking buffer ( 1 1 1  K), was added, and the plate was incubated at 3 7°C 
for 2 h. The plate was washed and then incubated for 1 h at 3 7°C with goat anti­
rabbit IgG HRP (Jackson; 50 )l l/wel l )  d i l uted in b locking buffer ( 1 :  1 5  K). After 
washing, the plate was incubated with 50 )l l/wel I SuperSignal EL ISA Femto 
E nhanced Chemi luminescent Substrate (Pierce). The chemi luminescence, in 
relative l ight units was measured immediately using a Victor3 1 420 (Wallac) 
microplate reader. The samples were screened in a bl inded fashion and tested 
randomly. The case and control samples were run on a single p late to avoid plate­
to-plate variations, and the results were confirmed using at least two independent 
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experiments. A series of  internal controls were also run to check for run-to-run 
variations. 
4.2 .4 Tran gen i c  m ice d e  c ri p t ion 
Mouse brains and microdialysis fluid were obtained from our col l aborator Dr. 
Louise Buur esterager (Lundbeck,  Denmark) .  
Approximatel 7 kb of the mouse o.-synucJein promoter was combined with 
human 0.- ynuclein c D  A and the SV40 poly-adenylation sequence in a construct 
used to e tabl ish transgenic mouse l ines by pronuclear microinjection into oocytes 
from C57BI6xD2 hybrids. The sub equent transgenic l ines were bred into C57Bl6 
m ice for a t  l east n ine generations. Non-transgenic mice from the same colony 
served as controls .  Expres i n of the transgene was assessed by Northern b lotting, 
1 11 i tu hybridization and Western blotting (Syn- l )  using standard methods 
( Westerlund et al . ,  2008) .  KO mice were created by replacing a 400 bp genomic 
fragment ontain ing the translocation start with a neocassette. WT mice in which 
the fragment was not knocked out were also used as controls. 
4 . 2 . 5  B r a i n  lysates p repara t i o n  
Frozen brain samples ( 1  g)  from Tg, WT and KO mice were homogenized in  
5 m l  o f  Cel Lyt ic buffer comprising mi ld detergent, bicine and 1 50 mM NaCl 
(S igma-Aldrich) and containing a cocktai l of  protease inhibitors inc luding AEBSF, 
aprotin in ,  E-64, E DT A and leupeptin ( Pierce) and then centri fuged at 3000 g for 
3 0  min .  The supernatant was col lected, and the total protein concentration was 
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measured. Al l amples were adjusted to 1 mglrnl and then stored at -80°C. The 
samples were thawed on ice directly prior to analysis. 
4.2.6 AD CSF b i o m a rkers 
Concentration [ t-tau, p-tau and AB-42 in CSF were determined using the 
andwich E l l  As Innotest™ B-Arnyloid ( 1 -42), Innotest hTAU-Ag and Innotest 
Pho photau ( l 8 I P) ·  l nnogenetics. Assay performance was monitored using pools  of 
urplus C F pec imen . For this purpose, mUltiple pools at varying concentrations 
were included in 7- 1 8  run . The interassay CVs obtained were 1 1 .3% for A �-42, 
9 . 3% for t-tau and 9 .4% for p-tau (Mulder et a1 . ,  20 1 0) . 
4.2.7 Prepal-a t ion  of the standards for the ol igo meric E L I SA 
Using an S O  gel,  recombinant a- yn purity was estimated to b e  > 95%. 
Oinsenoside Rb i (On Rb I )  stock solutions ( 1 0  mM) were prepared in 1 00% 
O M SO, and the final am unt of OMSO in the sample solutions was I %. Samples 
o f  25 /J.M a-syn in PBS ',: ere aged alone or with On Rb 1 at a molar ratio of  4: 1 
(CMC: a-syn molar ratio). The samples were placed 1 11 1 . 5 m l  steri le 
polypropylene tubes, drops of  mineral oi l were added to prevent sample 
evaporation, and the tubes were then sealed with parafi lm  and incubated at 3 7°C 
for 5 days with continuous shaking at 800 rpm in a Therrnomixer (Eppendorf) .  0-
a-Syn was then purified using FPLC (Ardah et a1. submitted for publ ication). 
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4 . 2 .8 S t u d  p o p u Jat ion  
The hwnan CSF samples were col l ected by our collaborator Dr .  Wi lma van de 
Berg (VU University Medical Center, Amsterdam) as described recently (van Dijk 
et al. ,  2014) .  In this study, we included 49 patients with PD that attended the 
outpatient c l in ic [or movement disorders at the VU University Medical Center 
bet\.v en eptcmber 2008 and February 20 1 1 , and 49 sel f-declared healthy controls 
who wer recruited via an advertisement in the periodical of the Dutch Parkinson 
Foundation.  Al l  pat ient with PD fulfi l led the United Kingdom Parkinson's  
D isease Society Brain B ank c l inical diagnostic criteria ( Hughes Daniel, Ki l ford, 
& Lees, 1 992) .  Patients were included only if they were able to understand the 
tudy aim and procedure . M ini-Mental State Examinations ( M MSE) and/or 
neuropsychological as e sments of the patients did not indicate dementia. In the 
controls. individuals with dementia based on the Cambridge Cognitive 
E xamination Scale ( Roth et a\ . , 1 986) were excluded. Patients and controls 
underwent a standardized c l in ical assessment that included their medical history 
and a neurological examination. Disease duration was defined as the time period 
starting from the first motor symptom until the time of lumbar puncture. The 
severity of  parkinson ism and disease stage in the 'on' state were rated using the 
U PDRS- l l I  ( Fahn, 1 987 )  and the modified Hoehn and Yal i c lassification (H& Y;  
Jankovic e t  aI . ,  1 990) ,  re pectively. The study was approved by  the local ethics 
committee o [  the VU Un iversity Medical Center, and all participants provided 
written, informed consent. 
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CSF fluid was obtained by lumbar puncture and coll ec ted in  polypropylene 
co l lection tube . CSF was routinely assayed for cell counts, centrifuged at 1 800 g 
at 4°C for 1 0  min, al iquoted and stored at -80°C with in  2 h, consistent with 
publ ished guide l ines (Teunissen et aI . ,  2009). All the samples were screened in a 
b l inded fashion and were tested randomly. 
4 . 2 .9 Data A n a l ys is  
tatisticai analyses were performed usmg GraphPad Prism (version 5 .0)  
software and IBM SPSS software 2 1 .  Continuous variables were described using 
medians and range because the data distributions were skewed. Correlations were 
calculated using Speannan 's  Rho(r). Mann-Whitney U-tests were used for 
comparison between the two diagnostic groups (p < 0.05) .  The accuracy of the 
diagnostic value of the biomarkers was assessed based on the area under the c urve 
( AUC) of the receiver operating characteristic ( ROC) curve ( Eusebi ,  20 1 3 ; Haj ian­
T i l ak i ,  20 1 3 ;  Robin et ai . ,  20 1 1 ) .  Cut-off values were calculated using sensitiv ity 
and pec ific ity val ues that maximized Youden 's index (sensitivity + spec i ficity -
I ) . Al l CSF samples with > 500 erythrocytes/il l were excluded from further 
analysis becau e traces of blood may influence CSF a-syn l evels (Barbour, et a i . ,  
2008; Hong, et a1 . ,  20 1 0) .  
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4. 3 Re ults 
4.3 . 1  Devel o p m e n t  of E L I S As for mea u r i n g  a-syn species i n  h u ma n  CSF 
Total-ELISA 
We developed, val idated and optimized a sandwich-type ELISA for 
measuring t-a-syn levels in human CSF .  Assay conditions were first optimized 
u ing di fferent concentrations of the capture sheep anti-a-syn antibody (Syn- 1 40).  
Based on its ens i t iv ity and background signal 0 . 1 J.lg/ml of  the capture ant ibody 
\: as selected for ubsequent assays (see below) . The detection l imit  of the assay 
was as low as 50 pg/ml ,  which is 20-fold less than the concentration detected in 
human CSF ( Fig .  4. 1 A) .  The tandard curve for the EL ISA assay was constructed 
using d i fferent concentrat ions of recombinant human a-syn in solution. Serial 
d i lutions of  recombinant human �-syn and y-syn were also included as negative 
control ( Fig. 4 . 1 B). To exclude the possibi l ity of our assay exhibiting disparate 
day-to-day perfom1ance signal variab i l i ty was examined over several days (> 50 
plates analyzed thus far). Our assay displayed a high degree of  reproducibi l ity with 
a day-to-day (plate-t -plate) CY < 1 0% ( Fig. 4 .2A) .  Next, we confirmed that our 
a say permitted the direct quanti ficat ion of native a-syn in biological samples such 
as human CSF and Tg mouse-bra in lysates. a-Syn was detected in Tg mice and 
human CSF, whereas no signal was observed in WT or knock-out (KO) lysates 
(Fig .  4.2B) .  Moreover, recovery rates were determ ined by spiking recombi nant a­
syn into human CSF .  Our assay consistently featured a mean recovery rate > 90% 
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Fig. 4.2 : Characterization of total -ELISA reproducibi l ity, speci ficity and robustness. 
(A) Data shown are representative of 3 independent experiments using serial di lut ions 
of recombinant a-syn freshly prepared over 3 non-consecut ive days. Measurements 
were taken in dupl icate. and the results show the mean ± standard dev iation for each 
point. ( B) Antibody speci ficity detem1ination using murine brain Iysates and lluman 
C F .  Tg. WT and KO brain "" ere homogenized in Cel Lyt ic reagent, contain ing EDTA 
and protease inh ib i tors, and Iysates were di luted to SJ.Lg/ml .  (C) Assessment of a-syn 
recovery rate in human CSF.  The recovery rates were calculated from measured a-syn 
concentration relative to spiked amounts.  
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Phospho-ELISA 
For p-S 1 29-a-syn-spec i fic EL ISA, we fol lowed a similar protocol for 
optimizing with t-a-syn, where anti-Syn- 1 40 was used as the capture antibody and 
rabbit monoclonal anti-p-S 1 29-a-syn antibody (EP 1 536Y) was used as the 
reporter. To address the i ssue of speci ficity, serial d i lutions of recombinant human 
p- l 29-a-syn and a- yn were tested, and signal was detected only with the anti-p-
1 29-a-syn ( Fig .  3A) .  Using similar critelia (sensitivity, reproducibi l i ty and 
background s ignal) ,  optimal conditions were adopted for the assay ( Fig .  4 .3B) .  
Sensitivity wa as low as 20 pg/ml, and a standard curve with an R2 of 0 .999 was 
generated (F ig .  4 . 3B) .  Coeffic ients of variat ion (CYs) were calculated by repeated 
measurements on non-consecutive days, and the day-to-day (plate-to-plate) 
variab i li ty in signal wa < 1 5% (Fig .  4.4A). To explore the assay suitabi l ity for 
quantifying p-S 1 29-a-syn i n  biological fluids mult iple concentrations of 
recombinant h uman p-S 1 29-a-syn were spiked into human CSF. The mean 
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Fig.  4.3 :  Characterizat ion of  phospho-ELISA protocol. (A) Standard curves 
displaying the spec ificit ies and sensitivities for p-S 1 29-a-syn ( . )  and a-syn 
( . ) . (B )  H istogram representing the optimization of the capture antibody 
(Syn- 1 40) concentration.  
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Fig. 4 . 4 :  Characterizat ion of phospho-E LI SA reprod ucib i l i ty and 
robustness. 
(A) Exam i nat ion of I nterassay variab i l i ty .  Measurements were taken i n  
dupl icate a n d  t h e  resu l ts show t h e  mean ± standard dev i at ion for each 
point .  ( B )  A ssessment of a-syn recovery rate in h uman C F.  Recovery 
rates were calculated from measured a-syn concentrat ions re lat i ve to 
spiked amou nts. 
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Oligomeric-ELISA 
Following the complete characterization of our mAbs using monomeric and 
aggregated a-syn protein ( for details, see Section 3 .2),  we developed and 
optimized a sensitive and pec ific ELISA for detecting o-a-syn in human CSF. 
imi larly, our o l igomeric  EL ISA is based on a conventional sandwich ELISA 
ystem,  where o-a- yn is captured using one of  our highly speci fic anti-o-a-syn 
mAbs (Syn-02 : see ection 3 .2 .8 ) .  We focused on the pair Syn-02/FL- 1 40, which 
consistently generated more robust signals than other pairs (see Section 3 .2 .8) .  
Mult ip le  condit ions were tested to assess assay perfonnance. Serial d i lutions of  
recombinant human o-a-syn were run in dupl icate. The signal detected [or o-a-syn 
i ncreased with increasing concentrations of  Syn-02 (0 . 5  �g/m l compared with 0.2 
�lglml or 0 . 1 �glm l ;  F ig . .+ . S A ) .  Hov ever, the assay sensitivity did not improve 
\ ith coat ing at 0 . 5  �g/ m l  compared with 0.2 �g/ml (see Fig. 4 . S A ) .  Based on 
optimal ensit iv i ty, spec ific i ty, reproducibi l ity and background signal re ults, we 
e l ected 0 .2  �glm l for coat ing. Our assay spec i fic i ty toward o-a-syn was further 
a l i d ated because no signal was detected when �- or 'Y-syn ol igomers were used 
( Fig. 4 . SB ) .  The i ntra-assay and inter-assay prec i sion was < 1 0% (based on an 
examination o f  over 1 00 p lates; Fig. 4 .6A). To assess the spec i fici ty and sensi t i v i ty 
of our o l igomeric-ELISA for o-a-syn in biological amples, brain lysates and 
m icrodialysis fluid from young Tg m i ce that over-expressed h uman a-syn were 
used and WT and KO mice were also inc luded as negative controls .  As , 
anticipated, o-a-syn levels were signi ficant l y  greater in Tg mice compared with 
WT whereas no signal was detected in KO mice (Fig.  4 .6B) .  I n  paral le l ,  our assay 
quantified the levels of o-a-syn in human CSF successful ly ( Fig. 4 .6B) .  
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ext, we spiked increasing amounts of recombinant o-a-syn i nto human CSF 
sample . Interestingly the average recovery rates were > 95% (F ig. 4.6C). We 
estimated that the lower l imit  of detection of recombinant o-a-syn using this 
EL ISA was as low as 1 0  pglml based on the init ial concentration of the protein (5 
n glml ) .  Taken together, the results show that our ol igomeric-ELISA i s  speci fic, 
ensit i  e and reproducible, and it is thus suitable for the quantification of o-a-syn 
in biological sampl es. 
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Fig. 4 .5 :  Characterization of  ol igomelic-ELISA protocol .  CA ) Histograms 
representing the optimization o f  the capture antibody CSyn-02) concentration. 
(B)  tandard curve displaying the speci ficit ie and sensitivities for u- C + ), 
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Fig.  4 . 6 :  Characterizati on of total-Ell  A reproduc ib i l i ty, speci fic i ty and 
rob ustne s. 
( A )  Asse sment of  I nterassay variabi l i ty . Measurements were taken in 
dup l i cate, and the results show the mean ± standard deviation for each point .  
(B) Ant ibody spec i fic i ty detem1 ination using murine brain l ysates and human 
C F. Tg, WT and KO brain were homogen ized in CelLyt ic  reagent, 
conta in ing E DT A and protease inh ib itors, and Iysates were d i l uted to 5 j.lg/ml .  
( ) Assessment o f  u-svn recovery rate i n  human CSF. Recoverv rates were 
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4.3.2 De cr ipt i  e anal  i 
Patient demographic data and c l inical features are l isted in Table 4. 1 .  Subj ects 
wi th PD and healthy controls (HC) were matched for age but not for gender (p = 
0 .002) .  Becau e no sign i ficant d ifferences between PD and control groups were 
found with re pect to gender, we decided not to correct for gender. 
Ta b l e  4 . 1 : Demographic data and c l inical features for HC and PD. 
HC (n=48) PD (n=46) 
Age 62.9 ± 7 .2  62.8 ± 1 0. 1  
Female 
Male 
B I  od cel l s  per microl i ter 
D isea e duration (years) 
H oelm and Yahr  tage 
U PDRS- I l l  (motor score) 
MMSE score 
32  (66.6%) 
1 6  ( 33 . 3%) 
37 .3  ± 89' 0-490 
29 ± 1 . 1  
4 .3.3 C S F  b iom arkers i n  d i agnostic g ro u p  
1 8  (39%) 
28 (6 1 %) 
35 .6  ± 1 00; 0-499 
5 .6  ± 5 .2  
2 . 1 ± 0 .5  
2 1 .8 ± 7 .9 
28 .5  ± 1 .S 
Consistent with our previous reports (Parnetti, et a1 . ,  20 1 1 ; Tokuda, et a I . ,  
2006),  CSF t-a.-syn leve ls  were sign ificantly decreased in PD patients compared 
with HC (p < 0.000 1 ;  Fig. 4 .7  A). However the concentrations of CSF o-a.-syn and 
p-S 1 29-a-syn were sign ificantly greater in PD patients compared with HC (p < 
0 .000 1 ,  P < 0.0 1 ,  respectively) with considerable overlap noted between the two 
groups for p-S 1 29-a-syn (F ig .  4 .7B and C) .  I nterestingly, the o-a-synlt-a-syn ratio 
(%) sub tantia l ly improved the disc rimination between PD and HC (p < 0.000 1 )  by 
reducing the overlap between the two groups ( Fig. 4 .7E) .  The p-S 1 29-a.-synlt-a-
9 5  
yn ratio (%) was also significantly and consistently greater i n  the PD group (p < 
0.000 1 ·  Fig. 4 .7D) .  
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Fig. 4.7: Scatterplots of  CSF biomarkers values observed in PD and HC 
Individual values f the levels of  t-a.-syn (A), o-a.-syn (B),  p-S 1 29-a.-syn 
(C),  the % ratio of o-a.-synJt-a-syn (D)  and the % ratio p-S 1 29-a.-synJt-a­
syn (E )  in CSF from pat ients with PO (sol id c i rc les) and He (so l id 
triangle ) .  Med ian values are indicated with a hori zontal l ine. Signi ficant 
d i fferences are ind icated with * (p < 0.05), * *  (p < 0.0 1 )  or * * *  (p < 
0 .00 1 ) . 
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The mean SF t-tau, p-tau and Abeta-42 concentrations did not vary 
significantl y  between P D  and HC groups (p > 0.05 ; Fig. 4 .8A, B and C) . All CSF 
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Fig. 4.8:  Scatterplots of CSF biomarkers values ob erved in PD and He. 
Individual values of the level of t-tau (A), p-tau ( B) ,  AP-42 (C) and 
the 
ratio of t-au/t-a-syn (D)  in CSF from patients with PD (so l id c irc les
) and 
HC (sol id triangles). Med ian values are indicated with a horizon
tal l i ne. 
i gn i ficant di fferences are indicated with * (p < 0.05) ,  * *  (p < 0.0 1 )  or * * *  
(p < 0.00 1 ) . 
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Table 4.2 CSF biomarkers in HC and PD 
CSF Biomarker HC PD p-value 
t-a-syn (ng/ml)  1 .64 ( 1 .3 8-2.28) 1 . 34 ( 1 .22- 1 .6) < 0 .00 1 
o-a-syn (pg/rnl )  5 7  ( 36- 1 07)  1 1 6 ( 76- 1 70) < 0 .00 1 
p- 1 29-a- yn (pg/ml ) 222 ( 1 8 1 -275) 262 ( 207-296) 0.0 1 
t-tau (pg/ml )  229  ( 1 62-272) 1 90 ( 1 58-274) 0.6 
p-tau (pg/rnl) 42 ( 30-50) 40 ( 30-5 1 )  1 .0 
�42 (pg/m l)  996 ( 878- 1 1 53 )  967 ( 794- 1 077) 0 . 1 
o-a-synlt-a-syn ratio (%) 3.5 ( 2 .3- 6.2) 8 .9 ( 5 . 3- 1 2.2) < 0 .00 1 
p- 1 29-a- ynlt-a-syn ratio  (%) 1 3 .7 ( 9 .2- 1 9) 1 9 ( 1 6 - 23)  < 0 .00 1 
t-tault-a- yn ratio (%) 1 1 (9 - 1 8) 1 5 ( 1 2 - 1 8) 0.03 
4.3.4 Correl a t i o n  a n a lysis fo r CSF biomarkers 
I nterestingly, a s ign i ficant positive correlation between t-a-syn and t-tau was 
found within the PD group (p < 0.000 1 ,  r = 0.5) ,  i .e . ,  h igher t-tau levels were 
associated w i th h i gher a-syn levels (Fig.  4.9A). Simi larly, a signi ficant positive 
correlation wa noted between t-a-syn and p-tau within the PD group (p < 0.000 1 ,  r 
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Fig.  4.9 : Correlation of t-CL-syn with AD biomarkers. 
2 0  
t-CL-Syn correlations with t-tau (A) p-tau (B)  and A�-42 (C) .  A l l  
correlations were calculated with Spearman 's  rho (p < 0.05) .  
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2 S 
I n  contrast, o-a-syn and p-S 1 29-a-syn l evels did not correlate with any of AD 
CSF biomarkers ( t-tau, p-tau or Abeta-42) within the PD group (F ig. 4. l OA-F). 
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Fig. 4 . 1 0 : Correlation of  o-a-syn and p-S l 2-a-syn with AD biomarkers. 
o-a-Syn correl ations with t-tau (A) p-tau (C)  and A �-42 ( E) .  p-S 1 29-a-Syn 
correlations with t-tau (B)  p-tau (D) and A �-42 ( F). A l l  cOITelations were 
calcu lated with Spearman 's rho (p < 0.05) .  
1 00 
4.3.5 Correl ation a n a l  si between C S F  bioma rker a n d  c l i n ical param eters 
An i nverse sign i ficant correlation between t-a-syn and MMSE scores was 
ob erved (p == 0.003, r == 0.3 ;  Fig. 4. 1 1  D).  I n  contrast, t-a-syn did not correlate with 
disease duration, H &  Y stage or UPDRS score within the PD group (Fig .  4. 1 1  A-
C). 
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Fig. 4 . 1 1 :  t-a-Syn correlations with c l in ical parameters. 
Correlations of t-(1.- yn with disease duration (A), H& Y stage ( B) 
U PDRS scale (C) and MMSE scores (D) in PD group. Al l  
correlat ions were calculated with Spearman 's  rho (p < 0.05) .  
1 0 1  
A weak but significant negative correlation was noted between o-u-syn and 
d isease duration and H&Y stage (p = 0.025, r = 0.3  and p = 0.025,  r = 0.24, 
respectively; Fig. 4. 1 2A and B). o-u-Syn levels did not correlate with U PDRS or 
M MS E  scores (Fig. 4. 1 2C and D) . 
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Correlation of o-u- yn with d i sease duration (A) ,  H&Y grade (B) ,  U PDRS 
scale (C)  and MM E scores (D)  i n  PD group. A l l  correlat ions were calculated 
with Spearman ' s  rho (p < 0.05) .  
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p-S 1 29-a-Syn did not correlate with disease duration, H &Y stage or UPDRS 
scores within the PD group (Fig. 4. 1 3  A-D). 
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F ig. 4. 1 3 :  p-S 1 29-a-Syn correlations with c l in ical parameters. 
COlTelations of p-S 1 29-a-Syn with di sease duration (A), H&Y grade 
(B)  UPDR scale (C) and MMSE scores (D) i n  PD group. All  
correlat ions were calculated with Spearman 's  rho (p < 0.05) .  
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"'.3.6 RO ana ly i 
RO analyse showed a ensit ivity of  0.72 and a pecificity of 0.63 for t -(1-
yn alone ( C = 0 .7 1 ) . o-(1-S yn exhibited a enslt lvlty of 0 .74 and a pecificity of 
0 .65 ( C = 0 .79), \ herea p-S 1 29-(1-S yn exhibited a sensitivity of 0 .60 and a 
pec i fici ty o f  0 .65 ( C = 0.67).  A combinat ion of p-S 1 29-(1- yn with t-(1-syn 
performed belter than p-S 1 29-(1- yn alone, showing a sen it ivity for detecting PD 
patient ver'us HC of O. 1 and a pecificity of 0 .56 (AUC = 0.75). Overal l ,  the 0-(1-
'yTh t-(1-'yn ratio ( ° 0 ) achieved the be t d iagno t ic  performance, with a sensitivity of 
O .  1 and a pecificity of  0 .65 ( UC = 0.83 ;  Fig. 4 . 1 4) .  
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Fig. 4. 1 4  se of  receiver operating characteristic (ROC) curves for the 
levels of (1-syn species in  CSF. ROC curves based on logistic 
regression analyses for the classification of  PD patients versus control 
subj ects based on various predictors and combination of predictors. 
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1 . 1 2  Di cu iOIl 
To date, the only accepted c l in ical diagnostic c riteria for PD are based on 
motor symptoms. However, a substantial degeneration of dopaminergic neurons i n  
the S precedes the manifestation of  motor symptoms, making the establ ishment 
of an early diagnosis for PD during the pre-motor phase quite a chal lenge. 
Determ ining the mechanisms underlying the loss of the n igraJ dopaminergic 
neuron and the development of dementia in some PD cases represents another 
chal lenge to this field. Establ ishing accurate tests based on chemical analyses of 
blood or CSF is of great i mportance for both diagnostic accuracy and prognostic 
evaluation. In thi tudy, we describe the development of  speci fic,  sensit ive and 
rel iable ELI  A assays to detect di fferent forms of u-syn, and we then 
demon trated the ir  ut i l i ty in quant i fying u-syn species in CSF from PD and age­
matched healthy control . 
Our new EL ISA assays provide mUltiple improvements over other reported 
i mmunoassays. F i rst. our EL ISA design using 3 84-wel l plates is perfectly 
compatible for accommodating mult iple repl icates even with l imited a sample 
olume (50 !.11/we l l) .  econd, the enhanced sensit ivity shown by our assays 
val idates their u itab i l ity for the analysis of human CSF specimens. Our assays 
were shown to be highly target spec i fi c  based on several methods, including 
spec ifici ty validation of the employed antibodies to their respective antigens, using 
brain and b lood products from genetical ly modi fied mice (Tg, WT , KO) and 
monitoring assay precisions. Our ELlSAs are also highly robust because recovery 
rates from spike experiments were > 90%. 
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Tokuda el at. pre iously described the development of an ELISA for 
quantifying o-a-syn in human CSF using the same mAb for capture and (a 
biotinylated form) for detection when directed against an a-syn epitope (Tokuda, 
et a ! .  2006) .  Using thi s  EL ISA design, only o-a-syn species were quanti fied 
because they pos e s mult iple epitopes for recognition by capture and detection 
antibodie . 0 ignal wa detected for the monomeric-a-syn because the only 
avai lab le  epitope was al ready occupied by the capture antibody, precluding its 
binding to the detection antibody. However, heterophi l ic antibodies may interfere 
in this as ay format, l eading to false-positive signals (Sehl in  et aI . ,  20 1 0).  
H eterophi l ic antibodies are polyreactive antibodies that recognize antibodies from 
the same specie and that may crossl ink the capture antibody to the detection 
antibody. Our new o l igomeric-ELI SA has addressed this shortcoming by using our 
novel conformation-spec i fic mAb (Syn-02), which selectively distinguishes and 
captures o-a-syn ,  and a rabbit polyc lonal antibody ( FL- 1 40) for detection, thus 
pennitting the precise quantification of o-a-syn in biological san1ples. 
Our results for t-a-syn are consistent with other reported studies that showed 
decreased l evel of C F t-a-syn levels in PO patients compared with controls (Hal l 
et aI . ,  20 1 2 ;  Hong, et aI . ,  20 1 0; Kang et al . ,  20 1 3 ; Mol lenhauer, et a1 .  20 1 1 ;  
Mol lenl1auer et a i . ,  20 1 3 ; Pametti, el ai . ,  20 1 1 ;  Pametti, Farotti, et a! . 20 1 4; 
Tokuda, et a l . ,  2006; van Dijk, et ai . ,  20 1 4). Several research groups have 
attributed the observed reduction in t-a.-syn in CSF to cel lu lar mechanisms leading 
to a-syn sequestration in LBs (Stewart el aI . ,  20 1 4; Tokuda, et a1 . ,  2006) . 
However, results showing a lack of correlation between CSF a-syn levels and 
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disease severity and the existence of  a direct association between LB features and 
disease progression have challenged this hypothesis. Pathological dysfunction in  
the neurons secreting a-syn may also explain the reduction in CSF a-syn l evels. 
Zhang and col l eagues suggested that C F a-syn depletion is most l ikely due to 
compensatory mechanisms (Stewart, et aI . ,  20 1 4) .  Under pathological conditions, a 
port ion of  a-syn is converted into toxic aggregates that are eventual ly  sequestered 
in LBs.  The reduct ion in intracel lu lar a-syn levels shifts the normal homeostasis of  
funct ional a-syn between intra- and extra-ce l lu lar compartments. This  sh ift leads 
t a deplet ion of a-syn in CSF and the accumulation of  synapt ic a-syn (Stewart, et 
aI . ,  20 1 4) .  
T h e  U P DRS i s  the most commonl y  used c l inical scal e  to provide an efficient 
and flexible assessment of motor symptoms in PD patients and to monitor the 
degree of resul tant disabi l ity. However, thus far, no strong l inear relationship has 
been establ ished between UPDRS scores and the progressive nigrostriatal 
degeneration in PD, which may underl ie the absence of a correlation between CSF 
t-a-syn levels and U PDRS scores. CSF biomarkers mirror changes with in  the brain 
as an entire unit, whereas UPDRS scores primari l y  reflect changes in the 
n igrostriatal dopaminergic system. In addition compensatory responses in PD may 
further confound the correlation between CSF biomarkers and the severity of PD 
motor symptoms (Shi et aI . ,  20 1 1 ) . Moreover, DA replacement therapy provided to 
PD patients enhances motor function while showing l ittle or no effect on CSF 
protein concentrations ( Hong, et aI . ,  20 1 0; Shi, et aI . ,  20 1 1 ) . 
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I n  2000, Matt i la  et at. reported for the flfst time, a direct association between 
dementia and LBs in the cortex, i .e . ,  the greater the burden of LBs, the worse the 
cognitive function in PD patients (Matti la, R inne, Helenius, Dickson, & Raytta, 
2000) . Subsequently, several other studies reported similar findings (Hurtig et al . ,  
2000; Kavan et al . 2003) .  imi larly, given the proposed role of a-syn in synaptic 
transmi sion ( heng Vivacqua, & Yu, 20 1 1 ), it is possible that altered a-syn 
levels play a cli tical role  in cognitive impairment. However, the association 
between t-a-syn levels and cognit ive impainnent is not yet ful ly  understood. The 
in rse correlation between t-a-syn and MMSE scores, although weak, i s  
tatistical ly significant and may be interpreted using the previously described 
hypothes i s  in which a-syn sequestrat ion in LBs results in increased a-syn 
accumulation at synapses (S tewart, et al . ,  20 1 4) .  
One  of  the most interesting findings in our study is the significant increase in  
CSF o-a-syn levels in  PD,  consistent with our previous studies using an 
o l igomeric-specific EL ISA based on the use of the same rnAb for capturing and 
detection (El-Agnaf et al . ,  2006) .  I nterestingly, the o-a-synlt-a-syn ratio (%) 
further improved discrimination between PD and controls, emphasizing the 
usefulness of combining several CSF biomarkers for differential diagnosis of 
c l inically overlapping parkinsonian d iseases. 
The overlap of both pathological and c l inical features in patients with 
synucleinopathies and tauopathies dictates the necessity of combining different 
biomarkers to achieve an accurate d i fferential diagnosis. Several l i nes of evidence 
support a l ink between the pathogenic role of a-syn and tau in neurodegenerative 
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disorders. For example, a co-existence of a-syn and tau pathology has been 
detected in brains of patients with AD, PO and OLB (Vekrell is, Xilouri, 
E mmanoui l idou, Rideout, & Stefanis, 20 1 1 ) . Moreover, several in vitro and in vivo 
studies investigated interactions among a-syn , tau and A� proteins, showing that 
these proteins promote each other's aggregation and polymerization, leading to 
neuronal degeneration and worsening cognitive impairment (Clinton, Blurton­
Jones, Myczek, Trojanowski ,  & LaFerla, 20 1 0; Giasson et al . ,  2003; Je l l inger, 
20 1 1 ,  20 1 2 ; Waxman & Giasson, 20 1 1 ) .  These data further explain the positive 
cOlTelation between CSF t-a-syn and tau in the P O  group, indicating that both 
biomarkers respond simi larly to neurodegeneration. This finding is consistent with 
a study by Toledo el al. , who found a positive correlation between CSF t-a-syn 
and tau level in PO, AD and controls (Toledo, Korff, Shaw, Trojanowski , & 
Zhang, 20 1 3) .  I nterestingly, combining both CSF t-a-syn and tau l evels improved 
their diagnostic value substantial ly, as i l lustrated by the ROC analyses. However 
an under tanding of the exact assoc iat ion between CSF tau and a-syn species is 
more complex and goes beyond being simply a secondary response to neuronal 
damage. 
LBs are fonned primari ly from post-transnational ly mod ified forms of a-syn. 
One of these mod i fications is a-syn phosphory lation at Ser 1 29, which accounts for 
approx imate ly 90% of accumulated a-syn in LBs. Although p-S I 29-a-syn may be 
critical for PO pathogenesis it remains an open question whether p-S 1 29-a-syn 
promotes or protects against a-syn aggregates' tox ic ity. Thus far, only one report 
has shown a weak positive colTelation between p-S 1 29-a-syn and U PORS and that 
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a combination o f  CSF t-a-syn and p-S 1 29-a-syn improved the discrimination of 
PD from other forms of  parkinsonism ( Wang, et al . 20 1 2) .  Here, we have shown 
an increase i n  p-S 1 29-a-syn i n  the PD group compared with controls .  ROC 
anal y i revealed a reasonable diagnostic sensitivity and specificity in  
d i  fferent iating PD from controls based on  p-S 1 29-a-syn levels alone. However, the 
combination of CSF t-a-syn and p-S 1 29-a-syn levels further improved the 
di criminati e power. 
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1. 1 3  Conciu ion a n d  Future Per pective 
The most important feature of our mAbs is their abi l ity to detect different 
as embl ies of a-syn aggregates ranging from soluble ol igomers to mature insoluble 
fibri l s. Given this unique feature, our mAbs viewed as anti-pathogenic  a-syn 
antibodies that recognize a specific conformation present in early aggregates and 
that i s  maintained in mature fibri ls .  Considering the crit ical pathogen ic role  of a­
syn soluble aggregates, our novel antibodies may provide substantial diagnosti c  
and therapeutic opportunit ies. Using our novel mAbs, we have developed ELISAs 
to measure t-a-syn o-a-syn and p-S 1 29-a-syn species in human CSF. Combining 
mea urements of di fferent a-syn species in CS F, we observed marked differential 
C S F  pattern between PD and controls. Our results val idated the usefulness of 
combin ing mult iple CSF biomarkers in improving PD diagnostic accuracy and 
prognosis. 
There is a need for novel therapeutics against PD as tradit ional therapies only 
a i le  i ate the symptoms of PD. a-Syn is an attractive target as it  has a central role  in 
the pathogenesis of PD and given the speci fic i ty of our mAbs towards a-syn 
pathology, they might be of potential use for future therapy and could also serve to 
identi fy rel iable biomarkers for PD and other related disorders. 
B iomarkers that can aid diagnose PD at its pre-motor phase, help physicians to 
moni tor how PD patients progress with this condition and assess drug 
effectiveness are crit ical to develop new disease-modifying treatments. 
Furthermore good biomarkers could be used to predict the risk that a given patient 
w i l l  develop adverse drug effects. In our study, we showed the potential of some 
1 1 1  
CSF biomarkers that can be prorrusmg diagnostic tools for PD diagnosis and 
prognosis. Validation of  our assays is critical step that may aid in  the translation of 
PD CSF biomarkers i nto c l i nical practice. The major l imitation for the discovery 
o f  PD biomarkers is  the l ack of longitudinal studies; hopefully in  the near future 
we can validate our EL ISA assays in such study. Furthermore we strongly bel ieve 
that combined measurement of several CSF biomarkers in l arge cohorts w i l l  have 
great impact on both early diagnosis and prediction of disease progression. More 
important ly, future studies on CSF biomarkers of PD might help to reveal the 
underlying mechanisms behind the disease. 
1 1 2 
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